US20230127290A1 - Muscle regeneration - Google Patents
Muscle regeneration Download PDFInfo
- Publication number
- US20230127290A1 US20230127290A1 US17/976,101 US202217976101A US2023127290A1 US 20230127290 A1 US20230127290 A1 US 20230127290A1 US 202217976101 A US202217976101 A US 202217976101A US 2023127290 A1 US2023127290 A1 US 2023127290A1
- Authority
- US
- United States
- Prior art keywords
- derivative
- elastase inhibitor
- muscle
- elastase
- myopathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000009756 muscle regeneration Effects 0.000 title claims abstract description 59
- 239000003602 elastase inhibitor Substances 0.000 claims abstract description 119
- 210000003205 muscle Anatomy 0.000 claims abstract description 107
- 229940122858 Elastase inhibitor Drugs 0.000 claims abstract description 83
- 208000021642 Muscular disease Diseases 0.000 claims abstract description 61
- 201000009623 Myopathy Diseases 0.000 claims abstract description 61
- 210000000130 stem cell Anatomy 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 27
- 230000001172 regenerating effect Effects 0.000 claims abstract description 16
- 230000001737 promoting effect Effects 0.000 claims abstract description 7
- IJWCGVPEDDQUDE-YGJAXBLXSA-N (2s)-2-[[(1s)-2-[[(2s)-5-amino-1,5-dioxo-1-[[(2s)-1-oxopropan-2-yl]amino]pentan-2-yl]amino]-1-[(6s)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-2-oxoethyl]carbamoylamino]-4-methylpentanoic acid Chemical compound O=C[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)N[C@@H](CC(C)C)C(O)=O)[C@@H]1CCN=C(N)N1 IJWCGVPEDDQUDE-YGJAXBLXSA-N 0.000 claims description 32
- IJWCGVPEDDQUDE-UHFFFAOYSA-N Elastatinal Natural products O=CC(C)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)NC(CC(C)C)C(O)=O)C1CCN=C(N)N1 IJWCGVPEDDQUDE-UHFFFAOYSA-N 0.000 claims description 32
- 108010039262 elastatinal Proteins 0.000 claims description 32
- -1 GW475151 Chemical compound 0.000 claims description 30
- 201000006938 muscular dystrophy Diseases 0.000 claims description 23
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 22
- BTGNGJJLZOIYID-UHFFFAOYSA-N sivelestat Chemical compound C1=CC(OC(=O)C(C)(C)C)=CC=C1S(=O)(=O)NC1=CC=CC=C1C(=O)NCC(O)=O BTGNGJJLZOIYID-UHFFFAOYSA-N 0.000 claims description 14
- 229950009343 sivelestat Drugs 0.000 claims description 14
- 201000002481 Myositis Diseases 0.000 claims description 11
- QNQZWEGMKJBHEM-UHFFFAOYSA-N 6-methyl-5-(2-methylpyrazol-3-yl)-n-[(5-methylsulfonylpyridin-2-yl)methyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound O=C1N(C=2C=C(C=CC=2)C(F)(F)F)C(C)=C(C=2N(N=CC=2)C)C=C1C(=O)NCC1=CC=C(S(C)(=O)=O)C=N1 QNQZWEGMKJBHEM-UHFFFAOYSA-N 0.000 claims description 8
- 101710205374 Extracellular elastase Proteins 0.000 claims description 8
- 229950005666 alvelestat Drugs 0.000 claims description 8
- PJGDFLJMBAYGGC-XLPNERPQSA-N methoxysuccinyl-Ala-Ala-Pro-Val chloromethyl ketone Chemical compound COC(=O)CCC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)CCl PJGDFLJMBAYGGC-XLPNERPQSA-N 0.000 claims description 8
- YAJWYFPMASPAMM-HXUWFJFHSA-N (4s)-4-(4-cyano-2-methylsulfonylphenyl)-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-4h-pyrimidine-5-carbonitrile Chemical compound N#CC([C@H](N(C1=O)C)C=2C(=CC(=CC=2)C#N)S(C)(=O)=O)=C(C)N1C1=CC=CC(C(F)(F)F)=C1 YAJWYFPMASPAMM-HXUWFJFHSA-N 0.000 claims description 7
- YSIHYROEMJSOAS-UHFFFAOYSA-N 2-(5-amino-6-oxo-2-phenylpyrimidin-1-yl)-n-[1-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-3-methyl-1-oxobutan-2-yl]acetamide Chemical compound N=1N=C(C(C)(C)C)OC=1C(=O)C(C(C)C)NC(=O)CN(C(C(N)=CN=1)=O)C=1C1=CC=CC=C1 YSIHYROEMJSOAS-UHFFFAOYSA-N 0.000 claims description 7
- PGIVGIFOWOVINL-GOSISDBHSA-N 5-[(6r)-5-acetyl-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-1,6-dihydropyrimidin-6-yl]pyridine-2-carbonitrile Chemical compound C1([C@H]2NC(=O)N(C(C)=C2C(=O)C)C=2C=C(C=CC=2)C(F)(F)F)=CC=C(C#N)N=C1 PGIVGIFOWOVINL-GOSISDBHSA-N 0.000 claims description 7
- 229950002904 freselestat Drugs 0.000 claims description 7
- KRFSMLDUZFVINX-UHFFFAOYSA-N 1-(3-methylbenzoyl)indazole-3-carbonitrile Chemical compound CC1=CC=CC(C(=O)N2C3=CC=CC=C3C(C#N)=N2)=C1 KRFSMLDUZFVINX-UHFFFAOYSA-N 0.000 claims description 4
- HUTNOYOBQPAKIA-UHFFFAOYSA-N 1h-pyrazin-2-one Chemical compound OC1=CN=CC=N1 HUTNOYOBQPAKIA-UHFFFAOYSA-N 0.000 claims description 4
- RCPIMTCZGQJSGZ-HNNXBMFYSA-N 2-[2-[(3s)-3-(dimethylamino)pyrrolidin-1-yl]pyridin-3-yl]-5-ethyl-7-methoxy-3,1-benzoxazin-4-one Chemical compound O1C(=O)C=2C(CC)=CC(OC)=CC=2N=C1C1=CC=CN=C1N1CC[C@H](N(C)C)C1 RCPIMTCZGQJSGZ-HNNXBMFYSA-N 0.000 claims description 4
- XLBPOGKAGPNWFQ-UHFFFAOYSA-N 3,4,6,7-tetrahydro-1h-pyrrolo[3,4-d]pyrimidine-2,5-dione Chemical compound C1NC(=O)NC2=C1C(=O)NC2 XLBPOGKAGPNWFQ-UHFFFAOYSA-N 0.000 claims description 4
- JMWYNUHGKFJVIB-QGFXQWJDSA-N 3-[(3R,9S,12S,15S,18S,24S,30S,33S,36S,39S,42S,45S,48S)-12-(4-aminobutyl)-15-(3-amino-3-oxopropyl)-30-[(2S)-butan-2-yl]-39-[(1R)-1-hydroxyethyl]-33-(hydroxymethyl)-9-[(4-hydroxyphenyl)methyl]-36-methyl-45-octyl-2,8,11,14,17,23,29,32,35,38,41,44,47-tridecaoxo-1,7,10,13,16,22,28,31,34,37,40,43,46-tridecazapentacyclo[46.3.0.03,7.018,22.024,28]henpentacontan-42-yl]propanoic acid Chemical compound C([C@H]1C(=O)N2CCC[C@@H]2C(=O)N2CCC[C@H]2C(=O)N[C@H](C(N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N1)[C@@H](C)CC)[C@@H](C)O)=O)CCCCCCCC)C1=CC=C(O)C=C1 JMWYNUHGKFJVIB-QGFXQWJDSA-N 0.000 claims description 4
- YPTPFIYIWRKRIX-UHFFFAOYSA-N 4-[2,5-dioxo-1-[3-(trifluoromethyl)phenyl]-3,4,6,7-tetrahydropyrrolo[3,4-d]pyrimidin-4-yl]benzonitrile Chemical compound FC(F)(F)C1=CC=CC(N2C(NC(C3=C2CNC3=O)C=2C=CC(=CC=2)C#N)=O)=C1 YPTPFIYIWRKRIX-UHFFFAOYSA-N 0.000 claims description 4
- SMCMGLCPSSSOQE-NTZARQNWSA-N 4-n-(4-chlorophenyl)sulfonyl-1-n-[(2s)-3-methyl-1-oxo-1-[[(2s)-1-(1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl)pyrrolidine-2-carbonyl]amino]butan-2-yl]benzene-1,4-dicarboxamide Chemical compound N([C@@H](C(C)C)C(=O)NC(=O)[C@H]1N(CCC1)C(C(C)C)C(=O)C(F)(F)F)C(=O)C(C=C1)=CC=C1C(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 SMCMGLCPSSSOQE-NTZARQNWSA-N 0.000 claims description 4
- HQQTZCPKNZVLFF-UHFFFAOYSA-N 4h-1,2-benzoxazin-3-one Chemical compound C1=CC=C2ONC(=O)CC2=C1 HQQTZCPKNZVLFF-UHFFFAOYSA-N 0.000 claims description 4
- DRZXDZYWZSKFDL-UHFFFAOYSA-N 6-methoxy-1,1-dioxo-2-[[4-oxo-9-[2-(1-piperidinyl)ethoxy]-2-pyrido[1,2-a]pyrimidinyl]oxymethyl]-4-propan-2-yl-1,2-benzothiazol-3-one Chemical compound CC(C)C1=CC(OC)=CC(S2(=O)=O)=C1C(=O)N2COC(N=C12)=CC(=O)N1C=CC=C2OCCN1CCCCC1 DRZXDZYWZSKFDL-UHFFFAOYSA-N 0.000 claims description 4
- 102100021253 Antileukoproteinase Human genes 0.000 claims description 4
- 101710170876 Antileukoproteinase Proteins 0.000 claims description 4
- 108010015972 Elafin Proteins 0.000 claims description 4
- 102000002149 Elafin Human genes 0.000 claims description 4
- 102100031938 Eppin Human genes 0.000 claims description 4
- 101710075602 Eppin Proteins 0.000 claims description 4
- 108010084635 ICI 200880 Proteins 0.000 claims description 4
- 101500009605 Momordica charantia Elastase inhibitor 2 Proteins 0.000 claims description 4
- 101500009604 Momordica charantia Elastase inhibitor 3 Proteins 0.000 claims description 4
- 108050003874 Protein AMBP Proteins 0.000 claims description 4
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 4
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims description 4
- WBTCPVUCKKBWBS-UHFFFAOYSA-N azetidine-2,4-dione Chemical compound O=C1CC(=O)N1 WBTCPVUCKKBWBS-UHFFFAOYSA-N 0.000 claims description 4
- MDCUNMLZLNGCQA-HWOAGHQOSA-N elafin Chemical compound N([C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]2CSSC[C@H]3C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CSSC[C@H]4C(=O)N5CCC[C@H]5C(=O)NCC(=O)N[C@H](C(N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]5N(CCC5)C(=O)[C@H]5N(CCC5)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N4)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N3)=O)[C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N MDCUNMLZLNGCQA-HWOAGHQOSA-N 0.000 claims description 4
- UIYRKMRXXFXSTH-XUXIUFHCSA-N methoxysuccinyl-Ala-Ala-Pro-Ala chloromethyl ketone Chemical compound COC(=O)CCC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)CCl UIYRKMRXXFXSTH-XUXIUFHCSA-N 0.000 claims description 4
- 229950001125 midesteine Drugs 0.000 claims description 4
- PQKSGWWAKCJGLT-UHFFFAOYSA-N phenyl(pyrazol-1-yl)methanone Chemical compound C1=CC=NN1C(=O)C1=CC=CC=C1 PQKSGWWAKCJGLT-UHFFFAOYSA-N 0.000 claims description 4
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims description 4
- MKTVMEMIKNBVHI-UHFFFAOYSA-N s-[1-oxo-1-[(2-oxothiolan-3-yl)amino]propan-2-yl] thiophene-2-carbothioate Chemical compound C1CSC(=O)C1NC(=O)C(C)SC(=O)C1=CC=CS1 MKTVMEMIKNBVHI-UHFFFAOYSA-N 0.000 claims description 4
- SSIXEJUVMSOOTO-UHFFFAOYSA-N 1-aminoimidazolidin-4-one Chemical compound NN1CNC(=O)C1 SSIXEJUVMSOOTO-UHFFFAOYSA-N 0.000 claims description 3
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 claims description 3
- 206010010356 Congenital anomaly Diseases 0.000 claims description 3
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 claims description 3
- 201000001981 dermatomyositis Diseases 0.000 claims description 3
- 201000008319 inclusion body myositis Diseases 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 208000005987 polymyositis Diseases 0.000 claims description 3
- UFCZUKYPBPXODT-OFTZGUNKSA-N (3ar,6s,6as)-4-methylsulfonyl-1-[(e)-4-piperidin-1-ylbut-2-enoyl]-6-propan-2-yl-3,3a,6,6a-tetrahydro-2h-pyrrolo[3,2-b]pyrrol-5-one;hydrochloride Chemical compound Cl.C([C@@H]1[C@@H]2[C@@H](C(N1S(C)(=O)=O)=O)C(C)C)CN2C(=O)\C=C\CN1CCCCC1 UFCZUKYPBPXODT-OFTZGUNKSA-N 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 102000013997 Protein AMBP Human genes 0.000 claims 3
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 3
- DHIVBEZCBBHIPZ-UHFFFAOYSA-N 1-aminoimidazolidin-2-one Chemical compound NN1CCNC1=O DHIVBEZCBBHIPZ-UHFFFAOYSA-N 0.000 claims 1
- 230000001681 protective effect Effects 0.000 abstract description 7
- 239000003112 inhibitor Substances 0.000 abstract description 5
- 210000000663 muscle cell Anatomy 0.000 abstract description 4
- 230000008929 regeneration Effects 0.000 abstract description 3
- 238000011069 regeneration method Methods 0.000 abstract description 3
- 108010067372 Pancreatic elastase Proteins 0.000 description 96
- 102000016387 Pancreatic elastase Human genes 0.000 description 96
- 230000000694 effects Effects 0.000 description 64
- 241000699670 Mus sp. Species 0.000 description 32
- 239000000523 sample Substances 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 27
- 210000003098 myoblast Anatomy 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 239000000194 fatty acid Substances 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 239000000835 fiber Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 230000004069 differentiation Effects 0.000 description 8
- 108010028275 Leukocyte Elastase Proteins 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 206010016654 Fibrosis Diseases 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 102000007547 Laminin Human genes 0.000 description 6
- 108010085895 Laminin Proteins 0.000 description 6
- 208000010428 Muscle Weakness Diseases 0.000 description 6
- 206010048654 Muscle fibrosis Diseases 0.000 description 6
- 206010028372 Muscular weakness Diseases 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000024245 cell differentiation Effects 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000004761 fibrosis Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 210000002027 skeletal muscle Anatomy 0.000 description 6
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 206010028289 Muscle atrophy Diseases 0.000 description 5
- 102100033174 Neutrophil elastase Human genes 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 5
- 230000020763 muscle atrophy Effects 0.000 description 5
- 230000004220 muscle function Effects 0.000 description 5
- 201000000585 muscular atrophy Diseases 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000021268 myoblast fusion Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000001964 muscle biopsy Methods 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 210000003668 pericyte Anatomy 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102000004266 Collagen Type IV Human genes 0.000 description 2
- 108010042086 Collagen Type IV Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108010069091 Dystrophin Proteins 0.000 description 2
- 102000001039 Dystrophin Human genes 0.000 description 2
- 102100034239 Emerin Human genes 0.000 description 2
- 201000009344 Emery-Dreifuss muscular dystrophy Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108050001049 Extracellular proteins Proteins 0.000 description 2
- 208000037149 Facioscapulohumeral dystrophy Diseases 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 201000009110 Oculopharyngeal muscular dystrophy Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000006727 cell loss Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 229940096422 collagen type i Drugs 0.000 description 2
- 201000006815 congenital muscular dystrophy Diseases 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 201000009338 distal myopathy Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012909 foetal bovine serum Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000007489 histopathology method Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000003274 myotonic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000001646 side-population cell Anatomy 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 description 1
- IGAZHQIYONOHQN-UHFFFAOYSA-N Alexa Fluor 555 Chemical compound C=12C=CC(=N)C(S(O)(=O)=O)=C2OC2=C(S(O)(=O)=O)C(N)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C(O)=O IGAZHQIYONOHQN-UHFFFAOYSA-N 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000428352 Amma Species 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 229930091051 Arenine Natural products 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical class NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 102100039511 Chymotrypsin-C Human genes 0.000 description 1
- 102100035371 Chymotrypsin-like elastase family member 1 Human genes 0.000 description 1
- 102100023335 Chymotrypsin-like elastase family member 2A Human genes 0.000 description 1
- 102100023338 Chymotrypsin-like elastase family member 2B Human genes 0.000 description 1
- 102100023337 Chymotrypsin-like elastase family member 3A Human genes 0.000 description 1
- 102100023336 Chymotrypsin-like elastase family member 3B Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 102100021238 Dynamin-2 Human genes 0.000 description 1
- 206010050256 Dysstasia Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 1
- 101000889306 Homo sapiens Chymotrypsin-C Proteins 0.000 description 1
- 101000737684 Homo sapiens Chymotrypsin-like elastase family member 1 Proteins 0.000 description 1
- 101000907955 Homo sapiens Chymotrypsin-like elastase family member 2A Proteins 0.000 description 1
- 101000907961 Homo sapiens Chymotrypsin-like elastase family member 2B Proteins 0.000 description 1
- 101000907964 Homo sapiens Chymotrypsin-like elastase family member 3A Proteins 0.000 description 1
- 101000907951 Homo sapiens Chymotrypsin-like elastase family member 3B Proteins 0.000 description 1
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 1
- 101001010513 Homo sapiens Leukocyte elastase inhibitor Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 1
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102100032859 Protein AMBP Human genes 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940045942 acetone sodium bisulfite Drugs 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000005012 alkyl thioether group Chemical group 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960002997 dehydrocholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- CARVNSROHCBVAO-BUGJESOBSA-N depelestat Chemical compound O=C([C@H](C(C)C)NC(=O)CNC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H]2C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC=3C=CC=CC=3)C(=O)N[C@@H](CC=3C=CC=CC=3)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=3C4=CC=CC=C4NC=3)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=3C=CC=CC=3)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H]3CSSC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=4C=CC(O)=CC=4)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC=4C=CC(O)=CC=4)NC(=O)[C@H]4N(CCC4)C(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC3=O)C(C)C)CSSC2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(C)C)[C@@H](C)CC)C(C)C)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O)N1CCC[C@H]1C(O)=O CARVNSROHCBVAO-BUGJESOBSA-N 0.000 description 1
- 108010077021 depelestat Proteins 0.000 description 1
- 229950003912 depelestat Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 101150015424 dmd gene Proteins 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940087857 lupron Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000001665 muscle stem cell Anatomy 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- YNJORDSKPXMABC-UHFFFAOYSA-M sodium;2-hydroxypropane-2-sulfonate Chemical compound [Na+].CC(C)(O)S([O-])(=O)=O YNJORDSKPXMABC-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Definitions
- the present invention relates to elastase inhibitors for use in the promotion of muscle regeneration in the treatment of a myopathy.
- the invention also relates to methods of promoting muscle regeneration in the treatment of a myopathy, as well as pharmaceutical compositions comprising an elastase inhibitor for use in the promotion of muscle regeneration in the treatment of a myopathy.
- Myopathies are a group of neuromuscular disorders associated with muscle weakness due to the dysfunction of muscle fibres.
- Muscular dystrophies are a subgroup of myopathies, characterised by progressive weakening of the skeletal muscles. The weakening of the skeletal muscle is a result of defects in muscle proteins, which, in some cases, lead to muscle cell death.
- Duchenne muscular dystrophy is the most common form of muscular dystrophy. It affects 1 in approximately 3,500 live male births. Duchenne muscular dystrophy is a progressive muscle degenerative disorder characterised by muscle weakness and progressive muscle loss. In Duchenne muscular dystrophy most of the muscles of the body are affected leading to loss of independent ambulation by approximately the age of 12, cardiomyopathy by the age of 18 and subsequent loss of respiratory capacity in the second decade of life.
- the molecular cause of Duchenne muscular dystrophy is the lack of the cytoskeletal protein dystrophin, which links the cell cytoskeleton to the extracellular matrix and therefore distributes linearly the force generated during muscle fibre contraction.
- the muscle fibres become very sensitive to contraction-induced stress and are easily damaged. This causes the continuous formation of foci of injury in dystrophic muscle that are initially repaired through the regenerative activity of the local muscle stern cells.
- the muscle stem cell regenerative potential is exhausted early in life in patients with Duchenne muscular dystrophy leading to loss of muscle regeneration upon disease-induced injury and replacement of the damaged muscle tissue with scar tissue (fibrosis). Over time the muscle tissue is lost leading to muscle weakness and eventually complete loss of muscle function.
- the invention provides an elastase inhibitor for use in the promotion of muscle regeneration in the treatment of a myopathy.
- the invention provides a method for promoting muscle regeneration in a subject with a myopathy, the method comprising providing the subject with a therapeutically effective amount of an elastase inhibitor.
- the invention provides a pharmaceutical composition comprising an elastase inhibitor for use in the promotion of muscle regeneration in the treatment of a myopathy.
- the invention provides a method of determining effectiveness of a treatment in a subject with a myopathy, the method comprising the steps of:
- elastase inhibitors for use according to the first aspect of the invention may be incorporated into pharmaceutical compositions suitable for administration to a subject requiring promotion of muscle regeneration in the treatment of a myopathy.
- Such pharmaceutical compositions may afford suitable means by which a therapeutically effective amount of an elastase inhibitor is provided to a subject in the method of treatment according to the second aspect of the invention. Accordingly, it will be recognised that, except where the context requires otherwise, embodiments described in respect of one aspect of the invention will also be applicable to the other two aspects.
- the treatment the effectiveness of which is being determined may employ an elastase inhibitor for use according to the first aspect of the invention, or a pharmaceutical composition for use according to the third aspect of the invention, or may be a method of treatment in accordance with the second aspect of the invention.
- FIG. 1 Shows a graph comparing elastase levels in muscles from wild-type and dystrophic mice.
- FIG. 2 Shows graphs illustrating the effects of elastase on myoblast proliferation.
- FIG. 3 Shows graphs illustrating the effects of elastase on myoblast differentiation.
- FIG. 4 A graph illustrating the effects of elastase inhibitors on elastase activity in vitro
- FIG. 5 Illustrates the effects of elastase inhibitors on myoblast cells during muscle regeneration ex vivo.
- A shows pictures of myoblast cells cultured in the presence of elastase but with or without elastase inhibitors.
- B shows a graph illustrating the cell number per field of cells cultured in the presence of elastase but with or without elastase inhibitors.
- FIG. 6 Shows a graph illustrating the effects of the elastase inhibitor Elastatinal on muscle function in vivo.
- FIG. 7 Shows a graph comparing the levels of elastase activity in the serum of ale patients with Duchenne muscular dystrophy and in age-matched healthy male controls.
- FIG. 8 Illustrates the effects of elastases inhibitors on muscle fibre size.
- A shows a graph illustrating the frequency of myofibres of various size.
- FIG. 10 Illustrates the effects of elastase inhibitors on fibrosis and inflammation.
- A shows sections of gastrocnemius muscle from saline or Elastatinal treated mice stained with Picrosirius red. Darker staining shows collagen deposits.
- B shows a graph illustrating the percentage of fibrous tissue in saline or Elastatinal treated mice.
- C shows sections of gastrocnemius muscle from saline or Elastatinal treated mice stained with either anti-laminin antibodies or anti-CD45 antibodies.
- D shows a graph illustrating the area of tissue which stained positively with anti-CD45 antibodies.
- the inventors have surprisingly found that increased elastase levels, and especially increased neutrophil elastase levels, may impair muscle regeneration. Without wishing to be bound by any particular hypothesis, the inventors believe that increased elastase levels damage the extracellular matrix which may result in a loss of muscle progenitor cell (such as such as satellite cell, pericytes, myoendothelial cell, side population cell, mesenchymal stem cell or myoblast cell) regenerative potential.
- muscle progenitor cell such as such as satellite cell, pericytes, myoendothelial cell, side population cell, mesenchymal stem cell or myoblast cell
- loss of muscle progenitor cell regenerative potential impairs the capacity of muscle tissue to regenerate.
- the loss of muscle progenitor cell regenerative potential may be therefore associated with the progressive loss of muscle strength and muscle mass typically observed in patients diagnosed with a myopathy, in particular muscle dystrophy such as Duchenne muscle dystrophy.
- elastase inhibitors may have a protective effect on muscle progenitor cells and their regenerative potential, which aids muscle cell regeneration. This surprising finding gives rise to a new approach to the treatment of muscular dystrophies and other myopathies.
- the term “elastase inhibitor” refers to any compound capable of reducing elastase enzyme activity, and thereby promoting muscle regeneration.
- Elastases are proteases which cleave the extracellular protein elastin and other extracellular proteins such as laminins, collagens and fibronectin. Accordingly, the term “elastase inhibitor” encompasses any compound capable of reducing the ability of an elastase enzyme to cleave its protein substrate.
- elastase activity can be determined by measuring the fluorescence emitted by a fluorigenic peptide such as MeOSuc-Ala-Ala-Pro-Val-AFC or Suc-Ala-Ala-Ala-AMC. Fluorescence may be measured, for example, using a plate reader. Other suitable assays for measuring elastase activity will be known to the skilled person.
- These may include measuring the product generated by incubation with a fluorescently labelled peptide such as 5-FAM-Arg-Glu-Ala-Val-Val-Tyr or 5-FAM-Ala-Ala-Ala-Phe-Tyr-Asp using an instrument that detects the size of the fluorescently labelled probe.
- a fluorescently labelled peptide such as 5-FAM-Arg-Glu-Ala-Val-Val-Tyr or 5-FAM-Ala-Ala-Ala-Phe-Tyr-Asp
- an elastase inhibitor may reduce elastase enzyme activity by at least 30%, at least 40%, at least 50%, at least 60%, or at least 70%, or more compared to normal elastase enzyme activity.
- an elastase inhibitor may reduce elastase enzyme activity by at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or more compared to normal elastase enzyme activity.
- Normal elastase enzyme activity refers to the activity of an elastase enzyme without the presence of an elastase inhibitor.
- a suitable elastase enzyme inhibitor may reduce the activity of an elastase enzyme either ex vivo or in vivo.
- elastase inhibitor encompasses any compound capable of reducing the activity of one or more elastase enzymes selected from the group consisting of: neutrophil elastase, macrophage metailoelastase, chymotrypsin-like elastase family, member 1; chymotrypsin-like elastase family, member 2A; chymotrypsin-like elastase family, member 2B; chymotrypsin-like elastase family, member 3A; chymotrypsin-like elastase family, member 3B; and chymotrypsin C (caldecrin).
- a suitable elastase enzyme inhibitor may specifically inhibit the activity of neutrophil elastase enzyme.
- the neutrophil elastase enzyme is the enzyme encoded by the gene ELANE.
- the elastase inhibitor is an extracellular elastase inhibitor.
- the extracellular elastase inhibitor is an extracellular inhibitor of neutrophil elastase.
- An extracellular elastase inhibitor is any compound capable of reducing the activity of an elastase enzyme occurring outside the cell. Such elastase inhibitors may prevent the degradation of the extracellular matrix caused by increased levels and/or increased activity of extracellular elastase enzymes.
- an elastase inhibitor may be provided extracellularly at a site of a myopathy.
- an extracellular elastase inhibitor may be one that is unable to cross the cell membrane, and thereby enter a cell. It will be appreciated that extracellular inhibitors of elastase activity of this sort will not inhibit intracellular elastase activity if provided extracellularly at a site of a myopathy requiring treatment (for example, if provided systemically).
- a suitable elastase inhibitor may be selected from the group consisting of: Alvelestat, Elastatinal, Sivelestat, BAY85-8501, BAY-678, Freselestat, AZD9819, GW-311616A, POL6014, SSR 69071, GW475151, ICI 200,880 and AX-9657, Midesteine, 1-(3-methylbenzoyl)-1 H-indazole-3-carbonitrile, Elastase inhibitor II, Elastase inhibitor III, Elastase inhibitor V, N-(Methoxysuccinyl)-Ala-Ala-Pro-Val-chloromethyl ketone, 1,4-diarylpyrimidopyridazinyldione or a derivative thereof, 2-pyrazinone or a derivative thereof, 2-pyridone or a derivative thereof, pyridyl-3-yl-benzo[d][1,3]oxazin-4-one or a derivative thereof,
- the elastase inhibitor may be selected from the group consisting of: Alvelestat, Elastatinal, Sivelestat, BAY85-8501, BAY-678, Freselestat and AZD9819.
- a suitable elastase inhibitor may be exogenous or endogenous.
- an exogenous elastase inhibitor is one which is not naturally occurring in humans.
- an exogenous elastase inhibitor may be a synthetic small molecule, or an elastase inhibitor which is naturally found in bacteria (or other non-human organisms).
- An example of an elastase inhibitor which is naturally found in bacteria is Elastatinal.
- an endogenous elastase inhibitor is one which is naturally occurring in humans.
- an endogenous elastase inhibitor may be synthetically produced.
- Such a synthetically produced endogenous elastase inhibitor is one which has the same chemical structure as any elastase inhibitor that naturally occurs in humans.
- Endogenous elastase inhibitors may be particularly useful in the context of gene therapy. Such elastase inhibitors may be provided to the subject either directly or indirectly. Direct provision of an endogenous elastase inhibitor may involve administering to the subject the endogenous elastase inhibitor itself.
- indirect provision of an endogenous elastase inhibitor may involve administering a compound which will result in increased expression of an endogenous elastase inhibitor in the subject.
- the indirect provision of an endogenous elastase inhibitor may involve administering a nucleic acid which encodes an endogenous elastase inhibitor.
- the first and second aspects of the invention respectively relate to medical uses and methods of treatment for the promotion of muscle regeneration in the treatment of myopathies.
- a promotion of muscle regeneration may be due to the ability of elastase inhibitors to protect muscle progenitor cell regenerative potential.
- the promotion of muscle regeneration refers to any clinical improvement in muscle function, which may be demonstrated by increased muscle strength, increased muscle mass, reduced pseudohypertrophy and/or reduced muscle atrophy. The clinical improvement may be compared to the state that otherwise occurs in an untreated myopathy.
- muscle regeneration may be considered to be promoted if the muscle strength and/or muscle mass is increased by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70% or more as compared to control or the subjects own muscle strength and/or muscle mass prior to treatment.
- Methods for testing muscle strength may include a walk or run test, but other methods will be known to the skilled person.
- Methods for testing muscle mass include, for example, determining 24 hour urinary creatinine levels, or body scanning using methods such as Dual-Energy X-Ray Absorptiometry (DEXA), Total Body Potassium (TBK), Magnetic Resonance Imaging (MRI), Total Body Electrical Conductivity (TOBEC), and Computed Tomography (CT)
- DEXA Dual-Energy X-Ray Absorptiometry
- TK Total Body Potassium
- MRI Magnetic Resonance Imaging
- TOBEC Total Body Electrical Conductivity
- CT Computed Tomography
- muscle regeneration may be considered to be promoted if pseudohypertrophy and/or muscle atrophy is decreased by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70% or more as compared to control or pseudohypertrophy and/or muscle atrophy observed in the subject prior to treatment.
- a decrease in pseudohypertrophy may be observed by a reduction in size of the calf muscle.
- a decrease in muscle atrophy may, for example, be determined histologically. Other methods for assessing pseudohypertrophy and/or muscle atrophy will be known to the skilled person.
- elastase inhibitors to promote muscle regeneration in the treatment of myopathies is based on the inventor's surprising finding that elastase inhibitors have a protective effect on the regenerative potential of muscle progenitor cells associated with myopathies.
- muscle progenitor cells refers to cells selected from the group consisting of: satellite cells, pericytes, myoendothelial cells, side population cells, mesenchymal stem cells, and myoblasts. It will be appreciated that references to muscle progenitor cells within the present disclosure may be interpreted as referring to individual populations of such cells (for example solely satellite cells or solely myoblast cells), or to combinations of two, three, four, five, or six of these cell types.
- muscle regeneration may be considered to be promoted if the number of muscle progenitor cells has increased by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70% or more as compared to the number of muscle progenitor cells in a relevant control (such as a sample from the same subject prior to treatment).
- the elastase inhibitors achieve their therapeutic effect through promoting muscle regeneration by protecting muscle progenitor cells.
- the inventors believe that by protecting muscle progenitor cell regenerative potential, elastase inhibitors enable or enhance the growth of new or existing muscle fibres, particularly in individuals diagnosed with a myopathy. Accordingly, muscle regeneration may be considered to be promoted if the number of new muscle fibres is increased by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70% or more.
- muscle regeneration may be considered to be promoted if the thickness of existing muscle fibres is increased by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70% or more.
- the number of new muscle fibres, as well as the thickness of existing muscle fibres may, for example, be determined through histological analysis of muscles pre and post exposure to elastase inhibitors.
- muscle regeneration may be considered to be promoted if muscle fibre diameter has increased by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70% or more.
- Muscle fibre diameter may be determined using various methods known to the skilled person, including measuring the minimum Feret diameter or the area of a muscle fibre cross-section.
- Muscle fibre loss may result from a reduction in the number of muscle progenitor cells, reduction in muscle progenitor cells proliferation (in particular myoblast proliferation), reduction in muscle progenitor cell differentiation (in particular myoblast differentiation), a reduction in myoblast fusion and/or a reduction in myotube growth.
- the term “promotion of muscle regeneration” is intended to include one or more protective effects on muscle progenitor cells.
- Such protective effects may be selected from the group consisting of: increased muscle progenitor cell number, increased muscle progenitor cell proliferation, increased muscle progenitor cell differentiation, increased muscle progenitor cell survival, increased myoblast fusion, and/or increased myotube growth.
- muscle regeneration may be considered to be promoted if muscle progenitor cell number, muscle progenitor cell proliferation, muscle progenitor cell differentiation, muscle progenitor cell survival, myoblast fusion and/or myotube growth is increased by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70% or more.
- muscle regeneration may be considered to be promoted if muscle fibrosis is reduced.
- muscle fibrosis may be reduced by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70% or more. More suitably, muscle regeneration may be considered to be promoted if muscle fibrosis is reduced by at least 30%.
- the skilled person will appreciate that there are various methods for determining muscle fibrosis. Such methods may include a muscle biopsy to measure the extent of muscle fibrosis (for example pre- and post-treatment)
- the term “subject” as used herein, refers to any individual who may benefit from the promotion of muscle regeneration in the treatment of a myopathy.
- the subject may be a human subject.
- the human subject may be a child.
- An individual who may benefit from the promotion of muscle regeneration may have symptoms associated with a myopathy, such as muscle weakness and/or reduced muscle mass.
- the subject may be asymptomatic but at risk of developing such symptoms.
- Symptoms associated with muscle weakness and/or reduced muscle mass include, but are not limited to a difficulty in walking, difficulty in running, difficulty in standing up and/or difficulty in breathing.
- myopathies in particular myopathies associated with muscle inflammation.
- myopathies are characterized by increased infiltration of white blood cells (in particular neutrophils) in the muscles.
- a myopathy associated with muscle inflammation may be determined by histological analysis (such as haematoxylin and eosin staining) of a muscle biopsy.
- myopathies associated with muscle inflammation may be selected from the group consisting of polymyositis, dermatomyositis, inclusion body myositis, congenital inflammatory myopathy and muscular dystrophy.
- a subject may be any individual diagnosed with, or at risk of developing a myopathy.
- the subject may be an individual diagnosed with, or at risk of developing a myopathy associated with muscle inflammation.
- the subject may be diagnosed with, or at risk of developing polymyositis, dermatomyositis, inclusion body myositis, congenital inflammatory myopathy or a muscular dystrophy.
- a suitably muscular dystrophy may be selected from the group consisting of: Duchenne muscular dystrophy, Becker muscular dystrophy, congenital muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy, myotonic muscular dystrophy and oculopharyngeal muscular dystrophy.
- the subject may be diagnosed with, or at risk of developing Duchenne muscular dystrophy.
- a subject may be considered at risk, for example, due to a known predisposition, such as the presence of a mutation (for example the DMD gene) and/or a familial history.
- a subject at risk of developing symptoms associated with impaired muscle regeneration may be asymptomatic.
- the medical uses and methods of treatment of the first and second aspects of the invention are useful in the treatment of myopathies.
- the uses and methods of the first and second aspects of the invention may be employed in the treatment of muscular dystrophy.
- the muscular dystrophy may be Duchenne muscular dystrophy.
- treatment refers to an intervention which prevents the progression, or reduces partially or completely the clinical symptoms associated with a myopathy, such as muscular dystrophy, in a subject. Accordingly, the term “treatment” encompasses not only the therapeutic use of elastase inhibitors in a subject with the symptoms of a myopathy, such as muscular dystrophy, but also the use of elastase inhibitors in the treatment of a subject who does not exhibit the symptoms of the myopathy. Such uses may be of particular relevance to an asymptomatic subject known to carry a mutation which increases the subject's likelihood of developing a myopathy, such as muscular dystrophy.
- a therapeutically effective amount refers to an amount of elastase inhibitor, that when provided to the subject with a myopathy, is sufficient to promote muscle regeneration in the subject.
- promotion of muscle regeneration may be demonstrated by a clinical improvement of symptoms associated with reduced muscle regeneration.
- Other ways in which promotion of muscle regeneration may be demonstrated are considered elsewhere in this specification.
- an improvement in symptoms may be demonstrated by increased muscle strength and/or increased muscle mass.
- promotion of muscle regeneration may be demonstrated by an improvement in muscle pathology.
- an improvement in muscle pathology may be demonstrated by a decrease in muscle fibrosis, a decrease in muscle inflammation and an increase in muscle progenitor cell number, increase in muscle progenitor cell proliferation, increase in muscle progenitor cell differentiation, increase in myoblast fusion, increase in myotube growth, and/or increase in muscle progenitor cell survival.
- the therapeutically effective amount may vary depending on various factors, including the type of elastase inhibitor. Different types of elastase inhibitors will have a different half-life and/or bioavailability, which may alter the therapeutically effective amount.
- the therapeutically effective amount may also vary depending on the subject's age, weight and/or gender.
- a therapeutically effective amount of the elastase inhibitor Sivelestat may be between 1 and 10 mg/kg/day, suitably between 3 and 7 mg/kg/day, more suitable approximately 5 mg/kg/day.
- a therapeutically effective amount of the elastase inhibitor Depelestat may be between 0.5 and 7 mg/kg/day, suitably between 1.5 and 5 mg/kg/day, more suitably approximately 3 mg/kg/day.
- a therapeutically effective amount of the elastase inhibitor Alvelestat may be between 10 and 150 mg/day, suitably 50 and 100 mg/day, more suitably approximately 60 mg/day.
- the fourth aspect is based on the inventors' surprising finding that subjects with a myopathy, in particular with muscular dystrophy such as Duchenne muscular dystrophy, may have higher levels of elastase activity as compared to individuals without such a disease.
- the inventors believe that this finding may be of particular utility in determining or monitoring the effectiveness of a treatment in a subject with a myopathy.
- the fourth aspect relates to a method of determining the effectiveness of a treatment in a subject with a myopathy, the method comprising the steps of:
- the reference value may be based upon the elastase activity measured either in one or more samples from a control individual(s), or in one or more samples from a subject(s) diagnosed with a myopathy and who did not receive treatment.
- the reference value is based upon the elastase activity measured in one or more samples from control individual(s). In such an embodiment, if the elastase activity measured in a sample from a subject treated for a myopathy approximates the elastase activity measured in a sample(s) from the control individual(s), it provides an indication that the treatment is effective.
- the term “approximates” may be taken as referring to elastase activity which is within 0.5-fold or less, 0.4-fold or less, 0.3-fold or less, 0.2-fold or less, 0.1-fold or less, or 0.05-fold or less, from the reference value.
- the reference value is based upon the elastase activity measured in a sample(s) from an individual(s) with a myopathy who has not received treatment.
- the individual with a myopathy may be the subject themselves prior to receiving treatment.
- the elastase activity measured in a sample from a subject treated for a myopathy approximates the elastase activity measured in a sample from an individual with a myopathy, it may be an indication that the treatment is not effective.
- elastase activity measured in the sample from the subject treated for a myopathy is lower than the elastase activity measured in the sample from an individual with a myopathy, it may be an indication that the treatment is effective. It will be appreciated that any reduction in elastase activity as compared to a reference value based upon elastase activity in a sample from an individual with a myopathy may be an indication that the treatment is effective.
- elastase activity that is at least 0.05-fold, at least 0.1-fold, at least 0.2-fold, at least 0.3-fold, at least 0.4-fold, at least 0.5-fold or more, lower than the reference value, may be an indication that the treatment is effective.
- elastase activity may be measured with the use of the fluorigenic peptide Suc-Ala-Ala-Ala-AMC as further explained in the Examples section.
- sample refers to any suitable sample that provides an indication as to the elastase activity in the subject.
- the sample may be a solid sample or a body fluid sample.
- the sample may be a fluid sample selected from the group consisting of: a blood sample (for example, a whole blood sample, a blood plasma sample, or a serum sample) and a urine sample. More suitably, the sample is a serum sample.
- a suitable solid sample may be a muscle biopsy.
- the pharmaceutical composition may comprise an elastase inhibitor and a pharmaceutically acceptable carrier.
- the pharmaceutical composition may comprise any elastase inhibitor disclosed herein. More suitably, the elastase inhibitor may be selected from the group consisting of: Alvelestat, Sivelestat, BAY85-8501, BAY-678, Freselestat and AZD9819.
- the “term pharmaceutically acceptable carrier” as used herein refers to any suitable diluent, excipient, or a combination thereof, suitable for administration into a subject.
- a pharmaceutically acceptable carrier may be an organic or inorganic substance, which facilities the delivery of an elastase inhibitor to the subject.
- a pharmaceutical composition of the invention may further comprise a pharmaceutically acceptable concentration of salt, buffering agents, and compatible carriers.
- the compositions may also include antioxidants and/or preservatives. Suitable antioxidants may be selected from the group consisting of: mentioned thiol derivatives (e.g. thioglycerol, cysteine, acetylcysteine, cystine, dithioerythreitol, dithiothreitol, glutathione), tocopherols, butylated hydroxyanisole, butylated hydroxytoluene, sulfurous acid salts (e.g.
- Suitable preservatives may for instance be phenol, chlorobutanol, benzylalcohol, methyl paraben, propyl paraben, benzalkonium chloride and cetylpyridinium chloride.
- the pharmaceutical composition of the present invention may be for administration to the subject via any suitable route.
- a suitable route of administration may be selected from the group consisting of: oral, intramuscular, intravenous, intraperitoneal and subcutaneous. Other methods for administering pharmaceutical compositions will be known to the skilled in the art.
- the pharmaceutical composition of the present invention is for oral administration.
- suitable oral administration forms include solid dosage forms, such as capsules, tablets, powders and granules.
- the elastase inhibitor may be mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or one or more: a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol and silicic acid; b) binders such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; humectants such as glycerol; d)disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, aiginic acid, certain silicates and sodium carbonate; e) solution retarding agents such as paraffin; f) absorption accelerators such as quaternary ammonium compounds;
- the dosage form may also comprise buffering agents.
- Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycol, for example.
- oral formulations may contain a dissolution aid.
- the dissolution aid is not limited as to its identity so long as it is pharmaceutically acceptable.
- examples include nonionic surface agents, such as sucrose fatty acid esters, glycerol fatty acid esters, sorbitan fatty acid esters (e.g., sorbitan trioleate), polyethylene glycol, polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid esters, polyoxyethyiene alkyl ethers, methoxypolyoxyethylene alkyl ethers, polyoxyethylene alkylphenyl ethers, polyethylene glycol fatty acid esters, polyoxyethylene alkylamines, polyoxyethylene alkyl thioethers, polyoxyethylene polyoxypropylene copolymers, polyoxyethylene glycerol fatty acid esters, pentaerythritol fatty acid esters, propylene glycol monofatty acid esters, polyoxyethylene propylene glycol monofatty acid esters, polyoxy
- the pharmaceutical composition is for administration in liquid dosage form.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may contain inert diluents commonly used in the art such as water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan and mixtures thereof.
- the oral compositions may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavouring and perfuming agents.
- adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavouring and perfuming agents.
- Suspensions in addition to the elastase inhibitor, may contain suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminium metahydroxide, bentonite, agar-agar, and tragacanth and mixtures thereof.
- the pharmaceutical composition is for intramuscular administration.
- a sterile pharmaceutical composition may be especially desirable.
- a sterile pharmaceutical composition may be obtained, for example, by filtration though sterile filtration membranes.
- the pharmaceutical composition of the present invention may be for sustained release of the elastase inhibitor.
- a pharmaceutical composition may comprise semipermeable matrices of solid hydrophobic polymers containing the elastase inhibitor, wherein the matrices are in the form of shaped articles, films or microcapsules.
- sustained-release matrices include polyesters, hydrogels, copolymers of L-glutamic acid and amma ethyl-L-glutamate, non-degradable ethylene-vinyl acetate de radable lactic acid- lycolic acid copolymers such as the LUPRON DepotTM (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid.
- LUPRON DepotTM injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate
- poly-D-(-)-3-hydroxybutyric acid examples include polyesters, hydrogels, copolymers of L-glutamic acid and amma ethyl-L-glutamate, non-degradable ethylene-vinyl acetate de radable lactic acid- lycolic acid copolymers such as the LUPRON DepotTM
- the amount of elastase staining detected in dystrophic mice of 3 and 7.5 months of age was greater than the amount detected in wild type mice of the same age ( FIG. 1 ).
- the amount of elastase accumulated in dystrophic muscles from 7.5 month-old mice appeared to be greater than the amount detected in younger dystrophic mice, suggesting that elastase accumulates in dystrophic muscle as the disease progresses and muscle loses regenerative capacity.
- quadriceps muscles were collected from male dystrophic (mdx4cv strain) and age-matched male wild type mice (C57bl/6J), which share the same background and mdx4cv mice). The muscles were snap-frozen in liquid nitrogen-cooled isopentane on a mounting of optimal cutting temperature compound (OCT).
- OCT optimal cutting temperature compound
- muscle progenitors In response to muscle injury or disease (such as muscular dystrophy) locally resident muscle progenitors, which are normally dormant, become activated, proliferate and then differentiate into muscle cells to regenerate the muscle tissue. This process can be recapitulated ex vivo to study the molecular mechanisms that govern it and how regeneration can be impaired or improved.
- Muscle progenitors are usually derived from the muscle stern cells called satellite cells or, rarely, from non-satellite cell sources, such as pericytes, myoendothelial cells, mesenchymal stem cells, side population cells and myoblasts.
- myoblasts When myoblasts are kept in a petri dish in the presence of culture medium (Dulbecco modified Eagle's medium, DMEM) containing 10% of foetal bovine serum they proliferate, dividing approximately twice per day, and eventually they differentiate and fuse to one another generating structures called myotubes, which resemble muscle fibres. This process of differentiation into myotubes can be sped up by switching the growth medium (containing 10% foetal bovine serum) to differentiation medium (containing 3% horse serum).
- DMEM Dulbecco modified Eagle's medium
- Elastase is a protease that degrades proteins of the extracellular matrix to which cells adhere in vivo and ex vivo.
- Cell adhesion is important for cell proliferation and differentiation.
- Myoblasts cultured in growth medium and exposed to elastase show impaired expansion mostly due to cell detachment, which in turn induces cell death and impairs proliferation in the cells that do not die.
- elastase-induced impairment of proliferation FIG. 2
- differentiation FIG. 3
- Ki67 using a rabbit-anti Ki67 antibody from Abcam at 1:400
- DNA using DAPI at 2 ⁇ g/mL
- Proliferating cells were scored as percentage of Ki67+ cells over the total number of cells (DAPI+) ( FIG. 2 A ).
- Dividing cells FIG. 2 B ) were scored as percentage of Ki67+ cells in mitosis (identified by high Ki67 immunoreactivity and morphology) over the total number of DAPI+ cells.
- myoblasts were seeded at a density of 20,000 cells/well on 12-multiwell plates (Corning) that had been previously coated with either collagen type I, collagen type IV or laminin and grown for 24 hours in growth medium prior to switching to differentiating medium (DIEM+3% horse serum) and adding purified elastase at the concentration of 0.15 U/mL.
- DIEM+3% horse serum differentiating medium
- the culture medium was removed, the cells fixed with 4% paraformaldehyde and immunostained to detect the differentiation marker myosin heavy chain (MyHC, using a mouse monoclonal antibody from Developmental Studies Hybridoma Bank, clone MF20) and DNA (using DAPI at 2 ⁇ g/mL).
- MyHC myosin heavy chain
- the fusion index ( FIG. 3 A ) was calculated using a bespoke written script for Fiji (available at http://fiji.sc) which calculates the percentage of nuclei present in MyHC+ cells with more than one nucleus over the total number of nuclei present in MyHC+ cells.
- the total myotube area FIG.
- a fluorescent elastase substrate was incubated with either DMSO or with purified 0.75 U/mL of elastase that had been pre-incubated for 1 hour with either DMSO, or 100 ⁇ M Sivelestat, or 100 ⁇ M Elastatinal.
- the percentage of substrate cleavage was monitored over time by recording product formation every minute for 30 minutes (30 cycles of instrument recording) using a Pierce EZ-Reader. The results are plotted in duplicate and show that both Sivelestat and Elastatinal reduce elastase activity is cell culture medium by approximately 80%.
- dystrophic mice were treated with either the elastase inhibitor Elastatinal (dissolved in saline solution) or saline solution for 12 weeks and muscle fibre size was assayed.
- Elastatinal (Enzo Life Sciences) was dissolved in a saline solution (0.9% NaCl) to the concentration of 20 mg/mL and then, either 200 mg/Kg body weight of Elastatinal or an equal volume of saline solution were injected twice a week intraperitoneally into the dystrophic (mdx4cv) mice. After 12 weeks of treatment animals were culled and several muscles dissected, embedded in Optimal Cutting Medium (OCT, Fisher) and frozen in liquid nitrogen-cooled isopentane (Sigma) for histopathological analysis.
- OCT Optimal Cutting Medium
- FIG. 8 A shows the distribution of minimum Feret diameter values of at least 3,000 fibres measured across three biological replicates in Elastatinal-treated mice (black bars) and saline-treated mice (white bars).
- FIG. 8 B shows the average minimum Feret diameter in Elastatinal-treated mice and saline-treated mice. These day show that elastase inhibitors may promote muscle regeneration through increasing muscle fibre size.
- mice treated with Elastatinal showed improved muscle strength (grip strength) compared to mice treated with vehicle only, likely due to improved muscle regeneration achieved upon inhibition of elastase activity ( FIG. 6 ).
- the objective of this experiment was to determine whether elastase inhibitors can reduce inflammation and/or fibrosis.
- cross-sections of the gastrocnemius muscle of mice that were treated with either Elastatinal or saline solution were stained with Picrosirius red, or labelled with an anti-CD45 antibody or an anti-laminin antibody.
- Picrosirius red allows to differentiate between collagen and the rest of the tissue as it stains the collagen a different colour.
- the anti-CD45 antibody allows the detection of infiltrating leukocytes (which are a marker of inflammation), and the anti-laminin antibody allows the detection of the periphery of myofibres. Both, the amount of fibrosis and the amount of infiltrated CD45+ leukocytes were reduced with Elastatinal treatment, supporting the hypothesis that elastase activity inhibition reduces fibrosis and inflammation.
- mice were treated with an injection of 200 mg/kg of Elastatinal dissolved in a saline solution (0.9% NaCl) to a concentration of 20 mg/mL.
- Control mice were treated with an equal volume of saline.
- mice were culled and several muscles dissected, embedded in Optima Cutting Medium (OCT, Fisher) and frozen in liquid nitrogen-cooled isopentane (Sigma) for histopathological analysis.
- OCT Optima Cutting Medium
- Sigma liquid nitrogen-cooled isopentane
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides anelastase inhibitor for use in the promotion of muscle regeneration in the treatment of a myopathy, as well as a method for promoting muscle regeneration in a subject with a myopathy, the method comprising providing the subject with a therapeutically effective amount of an elastase inhibitor. Further provided is a pharmaceutical composition comprising anelastase inhibitor for use in the promotion of muscle regeneration in the treatment of a myopathy. Elastase inhibitors may have a protective effect on muscle progenitor cells and their regenerative potential, which aids muscle cell regeneration. By protecting regenerative potential of muscle progenitor cells, elastase inhibitors enable or enhance the gown of new or existing muscle fibres.
Description
- The present invention relates to elastase inhibitors for use in the promotion of muscle regeneration in the treatment of a myopathy. The invention also relates to methods of promoting muscle regeneration in the treatment of a myopathy, as well as pharmaceutical compositions comprising an elastase inhibitor for use in the promotion of muscle regeneration in the treatment of a myopathy.
- Myopathies are a group of neuromuscular disorders associated with muscle weakness due to the dysfunction of muscle fibres. Muscular dystrophies are a subgroup of myopathies, characterised by progressive weakening of the skeletal muscles. The weakening of the skeletal muscle is a result of defects in muscle proteins, which, in some cases, lead to muscle cell death. There are nine major types of muscular dystrophy: Duchenne muscular dystrophy, Becker muscular dystrophy, congenital muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy, myotonic muscular dystrophy and oculopharyngeal muscular dystrophy.
- Duchenne muscular dystrophy is the most common form of muscular dystrophy. It affects 1 in approximately 3,500 live male births. Duchenne muscular dystrophy is a progressive muscle degenerative disorder characterised by muscle weakness and progressive muscle loss. In Duchenne muscular dystrophy most of the muscles of the body are affected leading to loss of independent ambulation by approximately the age of 12, cardiomyopathy by the age of 18 and subsequent loss of respiratory capacity in the second decade of life.
- The molecular cause of Duchenne muscular dystrophy is the lack of the cytoskeletal protein dystrophin, which links the cell cytoskeleton to the extracellular matrix and therefore distributes linearly the force generated during muscle fibre contraction. In the absence of dystrophin, the muscle fibres become very sensitive to contraction-induced stress and are easily damaged. This causes the continuous formation of foci of injury in dystrophic muscle that are initially repaired through the regenerative activity of the local muscle stern cells. However, for unknown reasons, the muscle stem cell regenerative potential is exhausted early in life in patients with Duchenne muscular dystrophy leading to loss of muscle regeneration upon disease-induced injury and replacement of the damaged muscle tissue with scar tissue (fibrosis). Over time the muscle tissue is lost leading to muscle weakness and eventually complete loss of muscle function.
- To date there is no cure or effective treatment for Duchenne muscular dystrophy. The management is currently based on the use of corticosteroids, which delay loss of ambulation and cardiomyopathy but also cause significant side effects often poorly tolerated by children and teenagers with Duchenne muscular dystrophy.
- It is an aim of certain embodiments of the invention to obviate or mitigate at least some of the problems noted above. It is an aim of certain embodiments of the invention to provide agents for use in the promotion of muscle regeneration in the treatment of myopathies, such as muscular dystrophy. It is an aim of certain embodiments of the invention to provide methods of treatment for use in the promotion of muscle regeneration in the treatment of myopathies, such as muscular dystrophy. It is an aim of certain embodiments of the invention to provide pharmaceutical compositions for use in the promotion of muscle regeneration in the treatment of myopathies, such as muscular dystrophy.
- In a first aspect, the invention provides an elastase inhibitor for use in the promotion of muscle regeneration in the treatment of a myopathy.
- In a second aspect, the invention provides a method for promoting muscle regeneration in a subject with a myopathy, the method comprising providing the subject with a therapeutically effective amount of an elastase inhibitor.
- In a third aspect, the invention provides a pharmaceutical composition comprising an elastase inhibitor for use in the promotion of muscle regeneration in the treatment of a myopathy.
- In a fourth aspect, the invention provides a method of determining effectiveness of a treatment in a subject with a myopathy, the method comprising the steps of:
-
- measuring elastase activity in a sample from the subject;
- comparing the elastase activity in the subject's sample to a reference value, and
- thereby determining the effectiveness of the treatment.
- It will be appreciated that elastase inhibitors for use according to the first aspect of the invention may be incorporated into pharmaceutical compositions suitable for administration to a subject requiring promotion of muscle regeneration in the treatment of a myopathy. Such pharmaceutical compositions may afford suitable means by which a therapeutically effective amount of an elastase inhibitor is provided to a subject in the method of treatment according to the second aspect of the invention. Accordingly, it will be recognised that, except where the context requires otherwise, embodiments described in respect of one aspect of the invention will also be applicable to the other two aspects.
- It will also be appreciated that in the context of the fourth aspect of the invention, the treatment the effectiveness of which is being determined may employ an elastase inhibitor for use according to the first aspect of the invention, or a pharmaceutical composition for use according to the third aspect of the invention, or may be a method of treatment in accordance with the second aspect of the invention.
- Embodiments of the invention are further described herein with reference to the accompanying drawings, in which:
-
FIG. 1 Shows a graph comparing elastase levels in muscles from wild-type and dystrophic mice. -
FIG. 2 Shows graphs illustrating the effects of elastase on myoblast proliferation. -
FIG. 3 Shows graphs illustrating the effects of elastase on myoblast differentiation. -
FIG. 4A graph illustrating the effects of elastase inhibitors on elastase activity in vitro, -
FIG. 5 Illustrates the effects of elastase inhibitors on myoblast cells during muscle regeneration ex vivo. A shows pictures of myoblast cells cultured in the presence of elastase but with or without elastase inhibitors. B shows a graph illustrating the cell number per field of cells cultured in the presence of elastase but with or without elastase inhibitors. -
FIG. 6 Shows a graph illustrating the effects of the elastase inhibitor Elastatinal on muscle function in vivo. -
FIG. 7 Shows a graph comparing the levels of elastase activity in the serum of ale patients with Duchenne muscular dystrophy and in age-matched healthy male controls. -
FIG. 8 Illustrates the effects of elastases inhibitors on muscle fibre size. A shows a graph illustrating the frequency of myofibres of various size. B shows the average minimum Feret diameter of myofibres from mice treated with Elastatinal and control mice treated with saline. The error bars show +/− SEM. **=p<0.01 -
FIG. 9 Shows a graph illustrating the effects of elastase inhibitors on muscle strength measured by grip strength using the Kondziella's inverted screen test. The error bars show +/− SEM. **=p<0.01 -
FIG. 10 Illustrates the effects of elastase inhibitors on fibrosis and inflammation. A shows sections of gastrocnemius muscle from saline or Elastatinal treated mice stained with Picrosirius red. Darker staining shows collagen deposits. B shows a graph illustrating the percentage of fibrous tissue in saline or Elastatinal treated mice. C shows sections of gastrocnemius muscle from saline or Elastatinal treated mice stained with either anti-laminin antibodies or anti-CD45 antibodies. D shows a graph illustrating the area of tissue which stained positively with anti-CD45 antibodies. - The inventors have surprisingly found that increased elastase levels, and especially increased neutrophil elastase levels, may impair muscle regeneration. Without wishing to be bound by any particular hypothesis, the inventors believe that increased elastase levels damage the extracellular matrix which may result in a loss of muscle progenitor cell (such as such as satellite cell, pericytes, myoendothelial cell, side population cell, mesenchymal stem cell or myoblast cell) regenerative potential.
- It is established in the scientific literature that loss of muscle progenitor cell regenerative potential impairs the capacity of muscle tissue to regenerate. The loss of muscle progenitor cell regenerative potential may be therefore associated with the progressive loss of muscle strength and muscle mass typically observed in patients diagnosed with a myopathy, in particular muscle dystrophy such as Duchenne muscle dystrophy.
- The inventors have unexpectedly found that elastase inhibitors may have a protective effect on muscle progenitor cells and their regenerative potential, which aids muscle cell regeneration. This surprising finding gives rise to a new approach to the treatment of muscular dystrophies and other myopathies.
- In the context of the present invention, the term “elastase inhibitor” refers to any compound capable of reducing elastase enzyme activity, and thereby promoting muscle regeneration. Elastases are proteases which cleave the extracellular protein elastin and other extracellular proteins such as laminins, collagens and fibronectin. Accordingly, the term “elastase inhibitor” encompasses any compound capable of reducing the ability of an elastase enzyme to cleave its protein substrate.
- Several methods for measuring elastase enzyme activity are known in the art. Merely by way of example, elastase activity can be determined by measuring the fluorescence emitted by a fluorigenic peptide such as MeOSuc-Ala-Ala-Pro-Val-AFC or Suc-Ala-Ala-Ala-AMC. Fluorescence may be measured, for example, using a plate reader. Other suitable assays for measuring elastase activity will be known to the skilled person. These may include measuring the product generated by incubation with a fluorescently labelled peptide such as 5-FAM-Arg-Glu-Ala-Val-Val-Tyr or 5-FAM-Ala-Ala-Ala-Phe-Tyr-Asp using an instrument that detects the size of the fluorescently labelled probe.
- In a suitable embodiment, an elastase inhibitor may reduce elastase enzyme activity by at least 30%, at least 40%, at least 50%, at least 60%, or at least 70%, or more compared to normal elastase enzyme activity. Suitably, an elastase inhibitor may reduce elastase enzyme activity by at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or more compared to normal elastase enzyme activity. Normal elastase enzyme activity refers to the activity of an elastase enzyme without the presence of an elastase inhibitor.
- A suitable elastase enzyme inhibitor may reduce the activity of an elastase enzyme either ex vivo or in vivo.
- In a suitable embodiment term “elastase inhibitor” encompasses any compound capable of reducing the activity of one or more elastase enzymes selected from the group consisting of: neutrophil elastase, macrophage metailoelastase, chymotrypsin-like elastase family,
member 1; chymotrypsin-like elastase family, member 2A; chymotrypsin-like elastase family, member 2B; chymotrypsin-like elastase family, member 3A; chymotrypsin-like elastase family, member 3B; and chymotrypsin C (caldecrin). - Alternatively, a suitable elastase enzyme inhibitor may specifically inhibit the activity of neutrophil elastase enzyme. The neutrophil elastase enzyme is the enzyme encoded by the gene ELANE.
- In a suitable embodiment the elastase inhibitor is an extracellular elastase inhibitor. In a particularly suitable embodiment the extracellular elastase inhibitor is an extracellular inhibitor of neutrophil elastase.
- An extracellular elastase inhibitor is any compound capable of reducing the activity of an elastase enzyme occurring outside the cell. Such elastase inhibitors may prevent the degradation of the extracellular matrix caused by increased levels and/or increased activity of extracellular elastase enzymes.
- Suitably, an elastase inhibitor may be provided extracellularly at a site of a myopathy. In this context, an extracellular elastase inhibitor may be one that is unable to cross the cell membrane, and thereby enter a cell. It will be appreciated that extracellular inhibitors of elastase activity of this sort will not inhibit intracellular elastase activity if provided extracellularly at a site of a myopathy requiring treatment (for example, if provided systemically).
- A suitable elastase inhibitor may be selected from the group consisting of: Alvelestat, Elastatinal, Sivelestat, BAY85-8501, BAY-678, Freselestat, AZD9819, GW-311616A, POL6014, SSR 69071, GW475151, ICI 200,880 and AX-9657, Midesteine, 1-(3-methylbenzoyl)-1 H-indazole-3-carbonitrile, Elastase inhibitor II, Elastase inhibitor III, Elastase inhibitor V, N-(Methoxysuccinyl)-Ala-Ala-Pro-Val-chloromethyl ketone, 1,4-diarylpyrimidopyridazinyldione or a derivative thereof, 2-pyrazinone or a derivative thereof, 2-pyridone or a derivative thereof, pyridyl-3-yl-benzo[d][1,3]oxazin-4-one or a derivative thereof, 3,4,6,7-tetrahydro-1H-pyrrolo[3,4-d]pyrimidine-2,5-dione or derivative thereof, 4-(4-Cyano-2-thioaryl)-dihydropyrimidone or a derivative thereof, 4-(4-cyanophenyl)-1-(3-trifluoromethylphenyl)-3,4,6,7-tetrahydro-1H-pyrrolo[3,4-d]pyrimidine-2,5-dione or a derivative thereof, Azetidine-2, 4-dione or a derivative thereof, Benzoxazinone or a derivative thereof, Dihydropyrimidone or a derivative thereof, functionalized N-amino-4-imidazolidinone, N-Benzoyl pyrazole or a derivative thereof, Tetrazolopyrimidine or a derivative thereof, Serpinbl, Elafin, Alpha-1-antitrypsin, Protein AMBP, Antileukoproteinase, Eppin and Alpha-2-macroglobulin.
- More suitably, the elastase inhibitor may be selected from the group consisting of: Alvelestat, Elastatinal, Sivelestat, BAY85-8501, BAY-678, Freselestat and AZD9819.
- A suitable elastase inhibitor may be exogenous or endogenous.
- For the purpose of the present invention, an exogenous elastase inhibitor is one which is not naturally occurring in humans. Merely by way of example, an exogenous elastase inhibitor may be a synthetic small molecule, or an elastase inhibitor which is naturally found in bacteria (or other non-human organisms). An example of an elastase inhibitor which is naturally found in bacteria is Elastatinal.
- For the purpose of the present invention, an endogenous elastase inhibitor is one which is naturally occurring in humans. However, it will be appreciated that an endogenous elastase inhibitor may be synthetically produced. Such a synthetically produced endogenous elastase inhibitor is one which has the same chemical structure as any elastase inhibitor that naturally occurs in humans.
- Endogenous elastase inhibitors may be particularly useful in the context of gene therapy. Such elastase inhibitors may be provided to the subject either directly or indirectly. Direct provision of an endogenous elastase inhibitor may involve administering to the subject the endogenous elastase inhibitor itself.
- Merely by way of example, indirect provision of an endogenous elastase inhibitor may involve administering a compound which will result in increased expression of an endogenous elastase inhibitor in the subject. Alternatively, the indirect provision of an endogenous elastase inhibitor may involve administering a nucleic acid which encodes an endogenous elastase inhibitor.
- The first and second aspects of the invention respectively relate to medical uses and methods of treatment for the promotion of muscle regeneration in the treatment of myopathies. Such a promotion of muscle regeneration may be due to the ability of elastase inhibitors to protect muscle progenitor cell regenerative potential. In this context, the promotion of muscle regeneration refers to any clinical improvement in muscle function, which may be demonstrated by increased muscle strength, increased muscle mass, reduced pseudohypertrophy and/or reduced muscle atrophy. The clinical improvement may be compared to the state that otherwise occurs in an untreated myopathy.
- Accordingly, in one embodiment muscle regeneration may be considered to be promoted if the muscle strength and/or muscle mass is increased by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70% or more as compared to control or the subjects own muscle strength and/or muscle mass prior to treatment. Methods for testing muscle strength may include a walk or run test, but other methods will be known to the skilled person. Methods for testing muscle mass include, for example, determining 24 hour urinary creatinine levels, or body scanning using methods such as Dual-Energy X-Ray Absorptiometry (DEXA), Total Body Potassium (TBK), Magnetic Resonance Imaging (MRI), Total Body Electrical Conductivity (TOBEC), and Computed Tomography (CT)
- In a suitable embodiment, muscle regeneration may be considered to be promoted if pseudohypertrophy and/or muscle atrophy is decreased by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70% or more as compared to control or pseudohypertrophy and/or muscle atrophy observed in the subject prior to treatment. A decrease in pseudohypertrophy may be observed by a reduction in size of the calf muscle. A decrease in muscle atrophy may, for example, be determined histologically. Other methods for assessing pseudohypertrophy and/or muscle atrophy will be known to the skilled person.
- The ability of elastase inhibitors to promote muscle regeneration in the treatment of myopathies is based on the inventor's surprising finding that elastase inhibitors have a protective effect on the regenerative potential of muscle progenitor cells associated with myopathies.
- The term “muscle progenitor cells” as used herein, refers to cells selected from the group consisting of: satellite cells, pericytes, myoendothelial cells, side population cells, mesenchymal stem cells, and myoblasts. It will be appreciated that references to muscle progenitor cells within the present disclosure may be interpreted as referring to individual populations of such cells (for example solely satellite cells or solely myoblast cells), or to combinations of two, three, four, five, or six of these cell types.
- Such a protective effect on muscle progenitor cells in subjects with impaired muscle regeneration due to a myopathy such as Duchenne muscular dystrophy, may result in an increase in muscle progenitor cells. Thus, muscle regeneration may be considered to be promoted if the number of muscle progenitor cells has increased by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70% or more as compared to the number of muscle progenitor cells in a relevant control (such as a sample from the same subject prior to treatment).
- Suitably the elastase inhibitors achieve their therapeutic effect through promoting muscle regeneration by protecting muscle progenitor cells. The inventors believe that by protecting muscle progenitor cell regenerative potential, elastase inhibitors enable or enhance the growth of new or existing muscle fibres, particularly in individuals diagnosed with a myopathy. Accordingly, muscle regeneration may be considered to be promoted if the number of new muscle fibres is increased by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70% or more. Similarly, muscle regeneration may be considered to be promoted if the thickness of existing muscle fibres is increased by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70% or more. The number of new muscle fibres, as well as the thickness of existing muscle fibres may, for example, be determined through histological analysis of muscles pre and post exposure to elastase inhibitors. Suitably, muscle regeneration may be considered to be promoted if muscle fibre diameter has increased by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70% or more. Muscle fibre diameter may be determined using various methods known to the skilled person, including measuring the minimum Feret diameter or the area of a muscle fibre cross-section.
- The inventors believe that the protective effect of elastase inhibitors on muscle progenitor cell regenerative potential may prevent elastase induced loss of muscle fibres. Muscle fibre loss may result from a reduction in the number of muscle progenitor cells, reduction in muscle progenitor cells proliferation (in particular myoblast proliferation), reduction in muscle progenitor cell differentiation (in particular myoblast differentiation), a reduction in myoblast fusion and/or a reduction in myotube growth.
- Therefore, in the context of the present invention, the term “promotion of muscle regeneration” is intended to include one or more protective effects on muscle progenitor cells. Such protective effects may be selected from the group consisting of: increased muscle progenitor cell number, increased muscle progenitor cell proliferation, increased muscle progenitor cell differentiation, increased muscle progenitor cell survival, increased myoblast fusion, and/or increased myotube growth.
- In one embodiment, muscle regeneration may be considered to be promoted if muscle progenitor cell number, muscle progenitor cell proliferation, muscle progenitor cell differentiation, muscle progenitor cell survival, myoblast fusion and/or myotube growth is increased by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70% or more.
- In one embodiment, muscle regeneration may be considered to be promoted if muscle fibrosis is reduced. Suitably, muscle fibrosis may be reduced by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70% or more. More suitably, muscle regeneration may be considered to be promoted if muscle fibrosis is reduced by at least 30%. The skilled person will appreciate that there are various methods for determining muscle fibrosis. Such methods may include a muscle biopsy to measure the extent of muscle fibrosis (for example pre- and post-treatment)
- The term “subject” as used herein, refers to any individual who may benefit from the promotion of muscle regeneration in the treatment of a myopathy. The subject may be a human subject. Suitably, the human subject may be a child.
- An individual who may benefit from the promotion of muscle regeneration may have symptoms associated with a myopathy, such as muscle weakness and/or reduced muscle mass. Alternatively, the subject may be asymptomatic but at risk of developing such symptoms. Symptoms associated with muscle weakness and/or reduced muscle mass include, but are not limited to a difficulty in walking, difficulty in running, difficulty in standing up and/or difficulty in breathing.
- Disorders particularly associated with muscle weakness and/or impaired muscle regeneration include myopathies, in particular myopathies associated with muscle inflammation. Such myopathies are characterized by increased infiltration of white blood cells (in particular neutrophils) in the muscles. By way of example, a myopathy associated with muscle inflammation may be determined by histological analysis (such as haematoxylin and eosin staining) of a muscle biopsy. Merely by way of example, myopathies associated with muscle inflammation may be selected from the group consisting of polymyositis, dermatomyositis, inclusion body myositis, congenital inflammatory myopathy and muscular dystrophy.
- Accordingly, a subject may be any individual diagnosed with, or at risk of developing a myopathy. Suitably the subject may be an individual diagnosed with, or at risk of developing a myopathy associated with muscle inflammation. In particular, the subject may be diagnosed with, or at risk of developing polymyositis, dermatomyositis, inclusion body myositis, congenital inflammatory myopathy or a muscular dystrophy. A suitably muscular dystrophy may be selected from the group consisting of: Duchenne muscular dystrophy, Becker muscular dystrophy, congenital muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy, myotonic muscular dystrophy and oculopharyngeal muscular dystrophy. Suitably, the subject may be diagnosed with, or at risk of developing Duchenne muscular dystrophy.
- In a suitable embodiment, a subject may be considered at risk, for example, due to a known predisposition, such as the presence of a mutation (for example the DMD gene) and/or a familial history. Suitably, a subject at risk of developing symptoms associated with impaired muscle regeneration may be asymptomatic.
- The medical uses and methods of treatment of the first and second aspects of the invention are useful in the treatment of myopathies. In a suitable embodiment, the uses and methods of the first and second aspects of the invention may be employed in the treatment of muscular dystrophy. Suitably, the muscular dystrophy may be Duchenne muscular dystrophy.
- The term “treatment” as used herein refers to an intervention which prevents the progression, or reduces partially or completely the clinical symptoms associated with a myopathy, such as muscular dystrophy, in a subject. Accordingly, the term “treatment” encompasses not only the therapeutic use of elastase inhibitors in a subject with the symptoms of a myopathy, such as muscular dystrophy, but also the use of elastase inhibitors in the treatment of a subject who does not exhibit the symptoms of the myopathy. Such uses may be of particular relevance to an asymptomatic subject known to carry a mutation which increases the subject's likelihood of developing a myopathy, such as muscular dystrophy.
- The term “a therapeutically effective amount” as used herein, refers to an amount of elastase inhibitor, that when provided to the subject with a myopathy, is sufficient to promote muscle regeneration in the subject. Merely by way of example promotion of muscle regeneration may be demonstrated by a clinical improvement of symptoms associated with reduced muscle regeneration. Other ways in which promotion of muscle regeneration may be demonstrated are considered elsewhere in this specification. By way of example, an improvement in symptoms may be demonstrated by increased muscle strength and/or increased muscle mass.
- Additionally or alternatively, promotion of muscle regeneration may be demonstrated by an improvement in muscle pathology. Suitably, an improvement in muscle pathology may be demonstrated by a decrease in muscle fibrosis, a decrease in muscle inflammation and an increase in muscle progenitor cell number, increase in muscle progenitor cell proliferation, increase in muscle progenitor cell differentiation, increase in myoblast fusion, increase in myotube growth, and/or increase in muscle progenitor cell survival.
- It will be appreciated that the therapeutically effective amount may vary depending on various factors, including the type of elastase inhibitor. Different types of elastase inhibitors will have a different half-life and/or bioavailability, which may alter the therapeutically effective amount.
- The therapeutically effective amount may also vary depending on the subject's age, weight and/or gender.
- By way of example, a therapeutically effective amount of the elastase inhibitor Sivelestat may be between 1 and 10 mg/kg/day, suitably between 3 and 7 mg/kg/day, more suitable approximately 5 mg/kg/day. By way of example, a therapeutically effective amount of the elastase inhibitor Depelestat may be between 0.5 and 7 mg/kg/day, suitably between 1.5 and 5 mg/kg/day, more suitably approximately 3 mg/kg/day. By way of example, a therapeutically effective amount of the elastase inhibitor Alvelestat may be between 10 and 150 mg/day, suitably 50 and 100 mg/day, more suitably approximately 60 mg/day.
- The fourth aspect is based on the inventors' surprising finding that subjects with a myopathy, in particular with muscular dystrophy such as Duchenne muscular dystrophy, may have higher levels of elastase activity as compared to individuals without such a disease. The inventors believe that this finding may be of particular utility in determining or monitoring the effectiveness of a treatment in a subject with a myopathy.
- Accordingly, the fourth aspect relates to a method of determining the effectiveness of a treatment in a subject with a myopathy, the method comprising the steps of:
-
- measuring elastase activity in a sample from the subject;
- comparing the elastase activity in the subject's sample to a reference value, and
- thereby determining the effectiveness of the treatment.
- It will be appreciated that the reference value may be based upon the elastase activity measured either in one or more samples from a control individual(s), or in one or more samples from a subject(s) diagnosed with a myopathy and who did not receive treatment.
- In one embodiment, the reference value is based upon the elastase activity measured in one or more samples from control individual(s). In such an embodiment, if the elastase activity measured in a sample from a subject treated for a myopathy approximates the elastase activity measured in a sample(s) from the control individual(s), it provides an indication that the treatment is effective.
- By the same token, if the elastase activity measured in a sample from a subject treated for a myopathy does not approximate the elastase activity measured in a sample from a control individual, it may be an indication that the treatment is not effective. In the context of the present disclosure the term “approximates” may be taken as referring to elastase activity which is within 0.5-fold or less, 0.4-fold or less, 0.3-fold or less, 0.2-fold or less, 0.1-fold or less, or 0.05-fold or less, from the reference value.
- In another embodiment, the reference value is based upon the elastase activity measured in a sample(s) from an individual(s) with a myopathy who has not received treatment. Suitably, the individual with a myopathy may be the subject themselves prior to receiving treatment. In such an embodiment, if the elastase activity measured in a sample from a subject treated for a myopathy approximates the elastase activity measured in a sample from an individual with a myopathy, it may be an indication that the treatment is not effective.
- By the same token, if the elastase activity measured in the sample from the subject treated for a myopathy is lower than the elastase activity measured in the sample from an individual with a myopathy, it may be an indication that the treatment is effective. It will be appreciated that any reduction in elastase activity as compared to a reference value based upon elastase activity in a sample from an individual with a myopathy may be an indication that the treatment is effective. Suitably, elastase activity that is at least 0.05-fold, at least 0.1-fold, at least 0.2-fold, at least 0.3-fold, at least 0.4-fold, at least 0.5-fold or more, lower than the reference value, may be an indication that the treatment is effective.
- Methods for measuring elastase activity will be known to the skilled person. By way of example, elastase activity may be measured with the use of the fluorigenic peptide Suc-Ala-Ala-Ala-AMC as further explained in the Examples section.
- In the context of the present disclosure, the term sample refers to any suitable sample that provides an indication as to the elastase activity in the subject. The sample may be a solid sample or a body fluid sample.
- Suitably, the sample may be a fluid sample selected from the group consisting of: a blood sample (for example, a whole blood sample, a blood plasma sample, or a serum sample) and a urine sample. More suitably, the sample is a serum sample.
- A suitable solid sample may be a muscle biopsy.
- In one embodiment the pharmaceutical composition may comprise an elastase inhibitor and a pharmaceutically acceptable carrier. Suitably, the pharmaceutical composition may comprise any elastase inhibitor disclosed herein. More suitably, the elastase inhibitor may be selected from the group consisting of: Alvelestat, Sivelestat, BAY85-8501, BAY-678, Freselestat and AZD9819.
- The “term pharmaceutically acceptable carrier” as used herein refers to any suitable diluent, excipient, or a combination thereof, suitable for administration into a subject. A pharmaceutically acceptable carrier may be an organic or inorganic substance, which facilities the delivery of an elastase inhibitor to the subject.
- In a suitable embodiment, a pharmaceutical composition of the invention may further comprise a pharmaceutically acceptable concentration of salt, buffering agents, and compatible carriers. The compositions may also include antioxidants and/or preservatives. Suitable antioxidants may be selected from the group consisting of: mentioned thiol derivatives (e.g. thioglycerol, cysteine, acetylcysteine, cystine, dithioerythreitol, dithiothreitol, glutathione), tocopherols, butylated hydroxyanisole, butylated hydroxytoluene, sulfurous acid salts (e.g. sodium sulfate, sodium bisulfite, acetone sodium bisulfite, sodium metabisulfite, sodium sulfite, sodium formaldehyde sulfoxylate, sodium thiosulfate) and nordihydroguaiareticacid. Suitable preservatives may for instance be phenol, chlorobutanol, benzylalcohol, methyl paraben, propyl paraben, benzalkonium chloride and cetylpyridinium chloride.
- The pharmaceutical composition of the present invention may be for administration to the subject via any suitable route. A suitable route of administration may be selected from the group consisting of: oral, intramuscular, intravenous, intraperitoneal and subcutaneous. Other methods for administering pharmaceutical compositions will be known to the skilled in the art.
- In one embodiment, the pharmaceutical composition of the present invention is for oral administration. Suitable oral administration forms include solid dosage forms, such as capsules, tablets, powders and granules. In such solid dosage forms, the elastase inhibitor may be mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or one or more: a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol and silicic acid; b) binders such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; humectants such as glycerol; d)disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, aiginic acid, certain silicates and sodium carbonate; e) solution retarding agents such as paraffin; f) absorption accelerators such as quaternary ammonium compounds; g) wetting agents such as cetyl alcohol and glycerol monostearate; h) absorbents such as kaolin and bentonite clay and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate and mixtures thereof. In the case of capsules and tablets, the dosage form may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycol, for example.
- Suitably, oral formulations may contain a dissolution aid. The dissolution aid is not limited as to its identity so long as it is pharmaceutically acceptable. Examples include nonionic surface agents, such as sucrose fatty acid esters, glycerol fatty acid esters, sorbitan fatty acid esters (e.g., sorbitan trioleate), polyethylene glycol, polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid esters, polyoxyethyiene alkyl ethers, methoxypolyoxyethylene alkyl ethers, polyoxyethylene alkylphenyl ethers, polyethylene glycol fatty acid esters, polyoxyethylene alkylamines, polyoxyethylene alkyl thioethers, polyoxyethylene polyoxypropylene copolymers, polyoxyethylene glycerol fatty acid esters, pentaerythritol fatty acid esters, propylene glycol monofatty acid esters, polyoxyethylene propylene glycol monofatty acid esters, polyoxyethylene sorbitol fatty acid esters, fatty acid alkylolamides, and alkylamine oxides; bile acid and salts thereof (e.g., chenodeoxycholic acid, cholic acid, deoxycholic acid, dehydrocholic acid and salts thereof, and glycine or taurine conjugate thereof); ionic surface agents, such as sodium laurylsulfate, fatty acid soaps, alkylsulfonates, alkylphosphates, ether phosphates, fatty acid salts of basic amino acids; triethanolamine soap, and alkyl quaternary ammonium salts; and amphoteric surface agents, such as betaines and aminocarboxylic acid salts. Pharmaceutical compositions of the invention, comprising an elastase inhibitor may also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.
- In one embodiment, the pharmaceutical composition is for administration in liquid dosage form. Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the elastase inhibitor, the liquid dosage forms may contain inert diluents commonly used in the art such as water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan and mixtures thereof. Besides inert diluents, the oral compositions may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavouring and perfuming agents. Suspensions, in addition to the elastase inhibitor, may contain suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminium metahydroxide, bentonite, agar-agar, and tragacanth and mixtures thereof.
- In a suitable embodiment, the pharmaceutical composition is for intramuscular administration. In such an embodiment, a sterile pharmaceutical composition may be especially desirable. A sterile pharmaceutical composition may be obtained, for example, by filtration though sterile filtration membranes.
- In a suitable embodiment, the pharmaceutical composition of the present invention may be for sustained release of the elastase inhibitor. Such a pharmaceutical composition may comprise semipermeable matrices of solid hydrophobic polymers containing the elastase inhibitor, wherein the matrices are in the form of shaped articles, films or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels, copolymers of L-glutamic acid and amma ethyl-L-glutamate, non-degradable ethylene-vinyl acetate deradable lactic acid-lycolic acid copolymers such as the LUPRON Depot™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid.
- To study the impact of dystrophy-induced chronic elastase presence on muscle regeneration, we used a mouse model of Duchenne muscular dystrophy, the mdx4cv mouse strain. We collected muscle tissue from mdx4cv mice and sex- and age-matched wild type mice at two ages (3 and 7.5 months) and probed wild type and mdx4cv muscles with an antibody that detects neutrophil elastase. While wild type muscle sections contained elastase only around blood vessels, an accumulation of elastase around and inside muscle fibres was observed in dystrophic muscle sections. When quantified, the amount of elastase staining detected in dystrophic mice of 3 and 7.5 months of age was greater than the amount detected in wild type mice of the same age (
FIG. 1 ). Importantly, the amount of elastase accumulated in dystrophic muscles from 7.5 month-old mice appeared to be greater than the amount detected in younger dystrophic mice, suggesting that elastase accumulates in dystrophic muscle as the disease progresses and muscle loses regenerative capacity. - In order to evaluate the levels of elastase, quadriceps muscles were collected from male dystrophic (mdx4cv strain) and age-matched male wild type mice (C57bl/6J), which share the same background and mdx4cv mice). The muscles were snap-frozen in liquid nitrogen-cooled isopentane on a mounting of optimal cutting temperature compound (OCT). Samples were then cryosectioned, fixed with paraformaldehyde (4% in PBS, pH 7.4) and immunostained to detect neutrophil elastase (with a rabbit anti-elastase antibody from Boss used at 1:100), laminin (with a rat anti-laminin alpha-2 from Sigma Aldrich used at 1:200) and DNA (with DAPI diluted at 2 μg/mL). Primary antibodies were then detected using AlexaFluor-conjugated secondary antibodies both from Life Technologies and used at 1:500 dilution (anti-rabbit conjugated to Alexa555 and anti-rat conjugated to Alexa488). Sections were imaged on an inverted fluorescence microscope, EVOS-FL, Life Technologies. Quantification of the immunofluorescence data was performed with a bespoke written script for Fiji available at available at (http://fiji.sc). Data from 10 images across 3 biological replicates (N=30) were quantified and plotted as average±the standard error of the mean (
FIG. 1 ). - Elastase levels were assessed in serum samples from patients with Duchenne muscular dystrophy. Serum samples were collected from boys with the diseases and age-matched healthy boys recruited at Alder Hey Children's Hospital, Liverpool, UK. To measure elastase activity in serum, samples were incubated with the fluorigenic peptide Suc-Ala-Ala-Ala-AMC (PeptaNova) for three hours at 37° C. and then the amount of fluorescence produced by elastase-mediated cleavage of the fluorigenic peptide was read using a plate reader (Polar Star Optima, BMG Labtech) at 380 nm excitation wavelength and 450 nm emission wavelength. The average emission of three technical replicates for 6 control subjects and 7 Duchenne muscular dystrophy patients were measured. The results (
FIG. 7 ) show that elastase activity was markedly and significantly increased in the blood of boys with Duchenne muscular dystrophy compared to healthy controls. In order to determine whether the results were statically significant, the data were analysed using a two-tailed t-test comparing the averages of healthy controls and patients. - In response to muscle injury or disease (such as muscular dystrophy) locally resident muscle progenitors, which are normally dormant, become activated, proliferate and then differentiate into muscle cells to regenerate the muscle tissue. This process can be recapitulated ex vivo to study the molecular mechanisms that govern it and how regeneration can be impaired or improved. Muscle progenitors are usually derived from the muscle stern cells called satellite cells or, rarely, from non-satellite cell sources, such as pericytes, myoendothelial cells, mesenchymal stem cells, side population cells and myoblasts. When myoblasts are kept in a petri dish in the presence of culture medium (Dulbecco modified Eagle's medium, DMEM) containing 10% of foetal bovine serum they proliferate, dividing approximately twice per day, and eventually they differentiate and fuse to one another generating structures called myotubes, which resemble muscle fibres. This process of differentiation into myotubes can be sped up by switching the growth medium (containing 10% foetal bovine serum) to differentiation medium (containing 3% horse serum).
- Elastase is a protease that degrades proteins of the extracellular matrix to which cells adhere in vivo and ex vivo. Cell adhesion is important for cell proliferation and differentiation. Myoblasts cultured in growth medium and exposed to elastase show impaired expansion mostly due to cell detachment, which in turn induces cell death and impairs proliferation in the cells that do not die. When myoblasts are seeded on specific substrates, elastase-induced impairment of proliferation (
FIG. 2 ) and differentiation (FIG. 3 ) is substrate-dependent manner, with laminin being the substrate that confers the highest sensitivity to elastase treatment. - In order to determine how elastase impairs myoblast proliferation, myoblasts were seeded at the density of 7,000 cells/well on 12 multi-well plates (Corning) that had been previously coated with either collagen type I, collagen type IV or laminin and grown for 24 hours in growth medium prior to adding purified elastase at either a concentration of 0.5 U/ml or 0.75 u=U/ml. After 24 h in the presence of elastase, the culture medium was removed, the cells fixed with 4% paraformaldehyde and immunostained to detect the proliferation marker Ki67 (using a rabbit-anti Ki67 antibody from Abcam at 1:400) and DNA (using DAPI at 2 μg/mL). Proliferating cells were scored as percentage of Ki67+ cells over the total number of cells (DAPI+) (
FIG. 2A ). Dividing cells (FIG. 2B ) were scored as percentage of Ki67+ cells in mitosis (identified by high Ki67 immunoreactivity and morphology) over the total number of DAPI+ cells. NT=non-treated cultures that did not receive elastase. *=p<0.05; **=p<0.01 - In order to determine how elastase impairs myoblast differentiation myoblasts were seeded at a density of 20,000 cells/well on 12-multiwell plates (Corning) that had been previously coated with either collagen type I, collagen type IV or laminin and grown for 24 hours in growth medium prior to switching to differentiating medium (DIEM+3% horse serum) and adding purified elastase at the concentration of 0.15 U/mL. After 4 days of differentiation in the presence of elastase, the culture medium was removed, the cells fixed with 4% paraformaldehyde and immunostained to detect the differentiation marker myosin heavy chain (MyHC, using a mouse monoclonal antibody from Developmental Studies Hybridoma Bank, clone MF20) and DNA (using DAPI at 2 μg/mL). The fusion index (
FIG. 3A ) was calculated using a bespoke written script for Fiji (available at http://fiji.sc) which calculates the percentage of nuclei present in MyHC+ cells with more than one nucleus over the total number of nuclei present in MyHC+ cells. The total myotube area (FIG. 3B ) was calculated using the above-mentioned bespoke written script for Fiji as the total area present in MyHC+ cells with more than one nucleus. NT=non-treated cultures that did not receive elastase, **=p<0.01. - Several elastase inhibitors have been developed. To study whether the elastase-Induced impairment in muscle regeneration could be reversed ex viva by elastase inhibitors, we tested different compounds for their efficacy at inhibiting elastase when present in cell culture medium (
FIG. 4 ). Both Sivelestat and Elastatinal (which are selective elastase inhibitors) were very effective at inhibiting elastase in cell culture medium. They reduced elastase activity by approximately 80% when used at the concentration of 100 μM (FIG. 4 ). - In order to determine the effects of elastase inhibitors on muscle regeneration ex vivo, a fluorescent elastase substrate was incubated with either DMSO or with purified 0.75 U/mL of elastase that had been pre-incubated for 1 hour with either DMSO, or 100 μM Sivelestat, or 100 μM Elastatinal. The percentage of substrate cleavage (substrate conversion to product) was monitored over time by recording product formation every minute for 30 minutes (30 cycles of instrument recording) using a Pierce EZ-Reader. The results are plotted in duplicate and show that both Sivelestat and Elastatinal reduce elastase activity is cell culture medium by approximately 80%.
- When myoblasts are seeded on uncoated plates and allowed to secrete their own extracellular matrix by culturing them in growth medium for one day, elastase-induced cell loss is still observed 24 hours after plating at an extent that is comparable to the loss observed when myoblasts are seeded on laminin (
FIG. 5A andFIG. 5B ). However, addition of elastase together with selective inhibitors of elastase activity, such as Sivelestat and Elastatinal, prevents elastase-induced cell loss. - In order to determine the effect of elastase inhibitors on cultures myoblasts, myoblasts were seeded at the density of 7,000 cells/well in 12 multi-well plates (Corning) and grown for 1 day in growth medium. Twenty-four hours after plating, 0.75 U/mL of purified elastase (Sigma Aldrich) were added to the culture medium in the absence (Ela) or presence of either 100 μM Sivelestat (Ela+Sivelestat) or 100 μM Elastatinal (Ela+Elastatinal) and cultured for additional 24 hours. Quantification of total cell numbers per image was done in triplicates and plotted as average±standard error of the mean. NT=non-treated cultures, that received neither elastase nor elastase inhibitors. **=p<0.01.
- To test whether inhibition of elastase activity promoted muscle regeneration in viva in dystrophic mice, dystrophic (mdx4cv strain) mice were treated with either the elastase inhibitor Elastatinal (dissolved in saline solution) or saline solution for 12 weeks and muscle fibre size was assayed.
- Elastatinal (Enzo Life Sciences) was dissolved in a saline solution (0.9% NaCl) to the concentration of 20 mg/mL and then, either 200 mg/Kg body weight of Elastatinal or an equal volume of saline solution were injected twice a week intraperitoneally into the dystrophic (mdx4cv) mice. After 12 weeks of treatment animals were culled and several muscles dissected, embedded in Optimal Cutting Medium (OCT, Fisher) and frozen in liquid nitrogen-cooled isopentane (Sigma) for histopathological analysis.
- To measure the extent of muscle regeneration, myofibre size was estimated. Sections of the gastrocnemius muscle of either Elastatinal-treated or saline-treated mice were immunostained to detect laminin which marks the periphery of each muscle fibre and then the programme SMASH1 was used to calculate the minimum Feret diameter as a direct measure of myofibre size.
FIG. 8A shows the distribution of minimum Feret diameter values of at least 3,000 fibres measured across three biological replicates in Elastatinal-treated mice (black bars) and saline-treated mice (white bars).FIG. 8B shows the average minimum Feret diameter in Elastatinal-treated mice and saline-treated mice. These day show that elastase inhibitors may promote muscle regeneration through increasing muscle fibre size. - To test whether elastase inhibition is effective in counteracting the devastating effects of the muscular dystrophy symptoms, we injected dystrophic (mdx4cv) mice with either 100 mg/Kg body weight of Elastatinal dissolved in sterile saline solution (0.9% NaCl2) or with vehicle (sterile saline solution) alone (n=3) twice a week for 6 weeks then measured the grip strength of ail 4 limbs using Kondziela's inverted screen test. Each animal was offered three attempts to reach 90 seconds of grip before falling then the best performance was assigned a score (1 to 6 for every 15 seconds spent on the grid, e.g.: 1-14 seconds=
score 1, 15-29 seconds=score 2, etc.). Scores were averaged and plotted as mean±the standard error of the mean. Mice treated with Elastatinal showed improved muscle strength (grip strength) compared to mice treated with vehicle only, likely due to improved muscle regeneration achieved upon inhibition of elastase activity (FIG. 6 ). - In addition to the above mentioned experiment, Elastatinal was dissolved in a saline solution (0.9% NaCl) to a concentration of 20 mg/mL and then either 200 mg/Kg body weight of Elastatinal or an equal volume of saline solution were injected twice a week for 12 weeks intraperitoneally into dystrophic (mdx4cv) mice. At 8, 10 and 12 weeks of treatment, muscle function (grip strength) of the mice was measured using Kondziella's inverted screen test. A 1-6 score was assigned for every 15 seconds of the total time spent by the mouse on the inverted grid such that a score of 6 indicates at least 90 seconds of latency to fall. As shown in
FIG. 9 , Elastatinal statistically significantly improved grip strength in dystrophic mice. Error bars are S.E.M. **=p<0.01. - The objective of this experiment was to determine whether elastase inhibitors can reduce inflammation and/or fibrosis. To test this, cross-sections of the gastrocnemius muscle of mice that were treated with either Elastatinal or saline solution were stained with Picrosirius red, or labelled with an anti-CD45 antibody or an anti-laminin antibody. Picrosirius red allows to differentiate between collagen and the rest of the tissue as it stains the collagen a different colour. The anti-CD45 antibody allows the detection of infiltrating leukocytes (which are a marker of inflammation), and the anti-laminin antibody allows the detection of the periphery of myofibres. Both, the amount of fibrosis and the amount of infiltrated CD45+ leukocytes were reduced with Elastatinal treatment, supporting the hypothesis that elastase activity inhibition reduces fibrosis and inflammation.
- For this experiment, the mice were treated with an injection of 200 mg/kg of Elastatinal dissolved in a saline solution (0.9% NaCl) to a concentration of 20 mg/mL. Control mice were treated with an equal volume of saline. After 12 weeks, mice were culled and several muscles dissected, embedded in Optima Cutting Medium (OCT, Fisher) and frozen in liquid nitrogen-cooled isopentane (Sigma) for histopathological analysis.
- The amount of Picrosirius red staining was quantified by selecting re pixels and quantifying the red area using the ImageJ function “Analyze particles”. Averages of 10 technical replicates for each one of 3 biological replicates (N=30) were analysed (
FIG. 10B ). - To measure the extent of inflammation, the numbers of infiltrating leucocyte, recognized by immunostaining for CD45 (BD Biosciences) were scored as percentage of area positive to CD45 immunostaining using a written script for Fiji softwate (available at http://fiji.sc) (
FIG. 10D ). -
- 1 Smith L R, Barton E R. SMASH—semi-automatic muscle analysis using segmentation of histology: a MATLAB application. Skelet Muscle. 2014 Nov. 27; 4:21.
Claims (24)
1. An elastase inhibitor for use in the promotion of muscle regeneration in the treatment of a myopathy.
2. An elastase inhibitor for use according to claim 1 , wherein the elastase inhibitor is for promoting muscle regeneration by protecting muscle progenitor cells.
3. An elastase inhibitor for use according to claim 1 , wherein the elastase inhibitor is provided in an amount sufficient to protect the regenerative potential of muscle progenitor cells.
4. An elastase inhibitor for use according to claim 1 , wherein the elastase inhibitor is an extracellular elastase inhibitor.
5. The elastase inhibitor for use according to claim 1 , wherein the elastase inhibitor is selected from the group consisting of: Alvelestat, Elastatinal, Sivelestat, BAY85-8501 , BAY-678, Freselestat, AZD9819, GW-31 1616A, POL6014, SSR 69071 , GW475151 , ICI 200,880 and AX-9657, Midesteine, 1-(3-methylbenzoyl)-1H-indazole-3-carbonitrile, Elastase inhibitor II, Elastase inhibitor III, Elastase inhibitor V, N-(Methoxy succinyl)-Ala-Ala-Pro-Val-chloromethyl ketone, 1,4-diarylpyrimidopyridazinyldione or a derivative thereof, 2-pyrazinone or a derivative thereof, 2-pyridone or a derivative thereof, pyridyl-3-yl-benzo[d][1,3]oxazin-4-one or a derivative thereof, 3,4,6,7-tetrahydro-1 H-pyrrolo[3,4-d]pyrimidine-2,5-dione or derivative thereof, 4-(4-Cyano-2-thioaryl)-dihydropyrimidone or a derivative thereof, 4-(4-cyanophenyl)-1-(3-trifluoromethylphenyl)-3,4,6,7-tetrahydro-1H-pyrrolo[3,4-d]pyrimidine-2,5-dione or a derivative thereof, Azetidine-2,4-dione or a derivative thereof, Benzoxazinone or a derivative thereof, Dihydropyrimidone or a derivative thereof, functionalized N-amino-4-imidazolidinone, N-Benzoyl pyrazole or a derivative thereof, Tetrazolopyrimidine or a derivative thereof, Serpinbl, Elafin, Alpha-1-antitrypsin, Protein AMBP, Antileukoproteinase, Eppin and Alpha macroglobulin.
6. An elastase inhibitor for use according to claim 5 , wherein the elastase inhibitor is selected from the group consisting of: Alvelestat, Elastatinal, Sivelestat, BAY85-8501 , BAY-678, Freselestat and AZD9819.
7. An elastase inhibitor for use according to claim 1 , wherein the promotion of muscle regeneration is for treatment of a myopathy associated with muscle inflammation.
8. An elastase inhibitor for use according to claim 7 , wherein the myopathy is selected from the group consisting of: muscular dystrophy, dermatomyositis, inclusion body myositis, congenital inflammatory myopathy and polymyositis.
9. An elastase inhibitor for use according to claim 8 , wherein the muscular dystrophy is Duchenne muscular dystrophy.
10. A method for promoting muscle regeneration in a subject with a myopathy, the method comprising providing a subject with a therapeutically effective amount of an elastase inhibitor.
11. A method according to claim 10 , wherein the therapeutically effective amount of the elastase inhibitor is sufficient to protect the regenerative potential of muscle progenitor cells.
12. A method according to claim 10 , wherein the elastase inhibitor is an extracellular elastase inhibitor.
13. A method according to claim 12 , wherein the elastase inhibitor is selected from the group consisting of: Alvelestat, Elastatinal, Sivelestat, BAY85-8501 , BAY-678, Freselestat, AZD9819, GW-311616A, POL6014, SSR 69071, GW475151, ICI 200,880 and AX-9657, Midesteine, 1-(3-methylbenzoyl)-1H-indazole-3-carbonitrile, Elastase inhibitor II, Elastase inhibitor III, Elastase inhibitor y, N-(Methoxysuccinyl)-Ala-Ala-Pro-Val-chloromethyl ketone, 1,4-diarylpyrimidopyridazinyldione or a derivative thereof, 2-pyrazinone or a derivative thereof, 2-pyridone or a derivative thereof, pyridyl-3-yl-benzo[d][1,3]oxazin-4-one or a derivative thereof, 3,4,6,7-tetrahydro-1 H-pyrrolo[3,4-d]pyrimidine-2,5-dione or derivative thereof, 4-(4-Cyano-2-thioaryl)-dihydropyrimidone or a derivative thereof, 4-(4-cyanophenyl)-1-(3-trifluoromethylphenyl)-3,4,6,7-tetrahydro-1H-pyrrolo[3,4-d]pyrimidine-2,5-dione or a derivative thereof, Azetidine-2,4-dione or a derivative thereof, Benzoxazinone or a derivative thereof, Dihydropyrimidone or a derivative thereof, functionalized N-amino-4-imidazolidinone, N-Benzoyl pyrazole or a derivative thereof, Tetrazolopyrimidine or a derivative thereof, Serpinbl, Elafin, Alpha-1-antitrypsin, Protein AMBP, Antileukoproteinase, Eppin and Alpha-2-macroglobulin.
14. (canceled)
15. A method according to claim 10 , wherein the promotion of muscle regeneration is for treatment of a myopathy associated with muscle inflammation.
16.-17. (canceled)
18. A pharmaceutical composition comprising an elastase inhibitor for use in the promotion of muscle regeneration in a myopathy.
19. A pharmaceutical composition for use according to claim 18 , wherein the elastase inhibitor is provided in an amount sufficient to protect the regenerative potential of muscle progenitor cells.
20. A pharmaceutical composition for use according to claim 18 , wherein the elastase inhibitor is an extracellular elastase inhibitor.
21. A pharmaceutical composition for use according to claim 20 , wherein the elastase inhibitor is selected from the group consisting of: Alvelestat, Elastatinal, Sivelestat, BAY85-8501, BAY-678, Freselestat, AZD9819, GW-31 1616A, POL6014, SSR 69071 , GW475151, ICI 200,880 and AX-9657, Midesteine, 1-(3-methylbenzoyl)-1 H-indazole-3-carbonitrile, Elastase inhibitor II, Elastase inhibitor III, Elastase inhibitor V, N-(Methoxysuccinyl)-Ala-Ala-Pro-Val-chloromethyl ketone, 1,4-diarylpyrimidopyridazinyldione or a derivative thereof, 2-pyrazinone or a derivative thereof, 2-pyridone or a derivative thereof, pyridyl-3-yl-benzo[d][1 ,3]oxazin-4-one or a derivative thereof, 3,4,6,7-tetrahydro-1 H-pyrrolo[3,4-d]pyrimidine-2,5-dione or derivative thereof, 4-(4-Cyano-2-thioaryl)-dihydropyrimidone or a derivative thereof, 4-(4-cyanophenyl)-1-(3 -trifluoromethylphenyl)-3 ,4, 6, 7-tetrahydro-1 H-pyrrolo[3,4-d]pyrimidine-2,5-dione or a derivative thereof, Azetidine-2, 4-dione or a derivative thereof, Benzoxazinone or a derivative thereof, Dihydropyrimidone or a derivative thereof, functionalized N-amino imidazolidinone, N-Benzoyl pyrazole or a derivative thereof, Tetrazolopyrimidine or a derivative thereof, Serpinbl , Elafin, Alpha-1 -antitrypsin, Protein AMBP, Antileukoproteinase, Eppin and Alpha-2-macroglobulin.
22. (canceled)
23. A pharmaceutical composition for use according to claim 18 , wherein the promotion of muscle regeneration is in treatment of a myopathy associated with muscle inflammation.
24.-25. (canceled)
26. A pharmaceutical composition for use according to claim 18 , for administration by a route selected from the group consisting of: oral, intramuscular, intravenous, intraperitoneal and subcutaneous.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/976,101 US20230127290A1 (en) | 2016-05-13 | 2022-10-28 | Muscle regeneration |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1608453.5 | 2016-05-13 | ||
GBGB1608453.5A GB201608453D0 (en) | 2016-05-13 | 2016-05-13 | Muscle regeneration |
GB1615529.3 | 2016-09-13 | ||
GBGB1615529.3A GB201615529D0 (en) | 2016-05-13 | 2016-09-13 | Muscle regeneration 2 |
US201816300283A | 2018-11-09 | 2018-11-09 | |
US17/104,192 US20210196694A1 (en) | 2016-05-13 | 2020-11-25 | Muscle regeneration |
US17/976,101 US20230127290A1 (en) | 2016-05-13 | 2022-10-28 | Muscle regeneration |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/104,192 Continuation US20210196694A1 (en) | 2016-05-13 | 2020-11-25 | Muscle regeneration |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230127290A1 true US20230127290A1 (en) | 2023-04-27 |
Family
ID=56320370
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/300,283 Active US10874652B2 (en) | 2016-05-13 | 2017-05-15 | Muscle regeneration |
US17/104,192 Abandoned US20210196694A1 (en) | 2016-05-13 | 2020-11-25 | Muscle regeneration |
US17/976,101 Pending US20230127290A1 (en) | 2016-05-13 | 2022-10-28 | Muscle regeneration |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/300,283 Active US10874652B2 (en) | 2016-05-13 | 2017-05-15 | Muscle regeneration |
US17/104,192 Abandoned US20210196694A1 (en) | 2016-05-13 | 2020-11-25 | Muscle regeneration |
Country Status (3)
Country | Link |
---|---|
US (3) | US10874652B2 (en) |
GB (2) | GB201608453D0 (en) |
WO (1) | WO2017194975A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2019257632A1 (en) | 2018-04-24 | 2020-11-26 | Ph Pharma Co., Ltd. | Use of neutrophil elastase inhibitors in liver disease |
US11918570B2 (en) | 2020-04-13 | 2024-03-05 | The Research Foundation For The State University Of New York | Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2564568A1 (en) * | 2004-04-20 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating inflammatory muscle disorders including myositis and muscular dystrophy |
GB201209138D0 (en) * | 2012-05-24 | 2012-07-04 | Ono Pharmaceutical Co | Compounds |
-
2016
- 2016-05-13 GB GBGB1608453.5A patent/GB201608453D0/en not_active Ceased
- 2016-09-13 GB GBGB1615529.3A patent/GB201615529D0/en not_active Ceased
-
2017
- 2017-05-15 US US16/300,283 patent/US10874652B2/en active Active
- 2017-05-15 WO PCT/GB2017/051349 patent/WO2017194975A1/en active Application Filing
-
2020
- 2020-11-25 US US17/104,192 patent/US20210196694A1/en not_active Abandoned
-
2022
- 2022-10-28 US US17/976,101 patent/US20230127290A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210196694A1 (en) | 2021-07-01 |
GB201608453D0 (en) | 2016-06-29 |
GB201615529D0 (en) | 2016-10-26 |
US20190134014A1 (en) | 2019-05-09 |
WO2017194975A1 (en) | 2017-11-16 |
US10874652B2 (en) | 2020-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230127290A1 (en) | Muscle regeneration | |
Kadri et al. | Osteoprotegerin inhibits cartilage degradation through an effect on trabecular bone in murine experimental osteoarthritis | |
US6649366B2 (en) | Methods and compositions related to modulators of annexin and cartilage homeostasis | |
Chen et al. | Lack of integrin α1β1 leads to severe glomerulosclerosis after glomerular injury | |
Zhao et al. | Naringin protects against cartilage destruction in osteoarthritis through repression of NF-κB signaling pathway | |
JP5481426B2 (en) | Sugar chain-related genes and their use | |
Ieronimakis et al. | Increased sphingosine-1-phosphate improves muscle regeneration in acutely injured mdx mice | |
JP2009525966A (en) | Compounds and methods for modulating protein transport | |
Wei et al. | Identification of fibroblast activation protein as an osteogenic suppressor and anti-osteoporosis drug target | |
Pavlidou et al. | Metformin delays satellite cell activation and maintains quiescence | |
Rossi et al. | Abnormal activity of the Na/Ca exchanger enhances glutamate transmission in experimental autoimmune encephalomyelitis | |
Carlson et al. | Chronic treatment with agents that stabilize cytosolic IκB-α enhances survival and improves resting membrane potential in MDX muscle fibers subjected to chronic passive stretch | |
US6379882B1 (en) | Method for selecting compounds for treating ischemia-related cellular damage | |
US20220193053A1 (en) | Cystic fibrosis transmembrane conductance regulator modulators for treating autosomal dominant polycystic kidney disease | |
Scheiber et al. | 4PBA reduces growth deficiency in osteogenesis imperfecta by enhancing transition of hypertrophic chondrocytes to osteoblasts | |
WO2011126882A2 (en) | Therapeutic peptides and their derivatives and therapeutic uses thereof | |
Cox et al. | The rheumatoid arthritis drug auranofin lowers leptin levels and exerts antidiabetic effects in obese mice | |
JP2017061539A (en) | Method of treatment using bcat1 inhibitor | |
Liu et al. | NF-κB-dependent production of nitric oxide by astrocytes mediates apoptosis in differentiated PC12 neurons following exposure to manganese and cytokines | |
CN101547688A (en) | Use of LXR agonists for the treatment of osteoarthritis | |
He et al. | Renal macrophages monitor and remove particles from urine to prevent tubule obstruction | |
Kitamura et al. | Effects of inhibition of myo-inositol transport on MDCK cells under hypertonic environment | |
WO2020006336A1 (en) | Treatment of cardiovascular calcification using nuclear export inhibitors | |
EP3043179A1 (en) | Methods and means for treatment of osteoarthritis | |
US20220119772A1 (en) | Compositions and methods for treatment of a malabsorptive disorder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION COUNTED, NOT YET MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |